var title_f28_35_29232="FAST subxiphoid normal cardiac motion";
var content_f28_35_29232=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1140px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/62533/FAST_subxiphoid_norm_movie.mp4?title=FAST+subxiphoid+normal+cardiac+motion\" style=\"width:496px;height:320px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    FAST: Subxiphoid view of normal cardiac motion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 389px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This video clip, obtained as part of a FAST examination, shows normal cardiac motion and no pericardial effusion.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29232=[""].join("\n");
var outline_f28_35_29232=null;
var title_f28_35_29233="Molluscum eyelid";
var content_f28_35_29233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75198&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum on the eyelid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Solitary nodule of molluscum contagiosum in the middle of the left lower lid. There are no signs of secondary conjunctivitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Gold, DH, Weingeist, TA. Color Atlas of the Eye in Systemic Disease, Lippincott Williams &amp; Wilkins, Baltimore 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29233=[""].join("\n");
var outline_f28_35_29233=null;
var title_f28_35_29234="Intravenous pyelogram showing massive bilateral hydronephrosis";
var content_f28_35_29234=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65559%7ENEPH%2F73212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65559%7ENEPH%2F73212&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intravenous pyelogram showing massive bilateral hydronephrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intravenous pyelogram showing massive bilateral hydronephrosis and ureteral dilatation (arrow) due to urinary tract obstruction which, as shown in the next film, is due to ureterovesical obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Rose BD, Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intravenous pyelogram showing ureterovesical junction obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pelvic view of intravenous pyelogram showing bilateral ureterovesical junction obstruction (arrows) with proximal ureteral dilatation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Rose BD, Pathophysiology of Renal Disease, 2d ed, McGraw-Hill, New York, 1987.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29234=[""].join("\n");
var outline_f28_35_29234=null;
var title_f28_35_29235="Brinzolamide: Drug information";
var content_f28_35_29235=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Brinzolamide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/38/15972?source=see_link\">",
"    see \"Brinzolamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F142340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azopt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F142341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Azopt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F142366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Carbonic Anhydrase Inhibitor;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F142343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Ocular hypertension or open-angle glaucoma:",
"     </b>",
"     Ophthalmic: Instill 1 drop in affected eye(s) 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F142344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13646015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute): Use is not recommended (has not been studied; brinzolamide and metabolite are excreted predominately by the kidney).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F142322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Azopt&reg;: 1% (10 mL, 15 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F142307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F142325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remove contact lenses prior to administration; wait 15 minutes before reinserting. If more than one topical ophthalmic drug is being used, administer drugs at least 10 minutes apart. Shake well before use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F142323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F142364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hyperemia (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Dermatitis (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Taste disturbances (5% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (5% to 10%), blepharitis (1% to 5%), dry eye (1% to 5%), eye discharge (1% to 5%), eye discomfort (1% to 5%), eye pain (1% to 5%), foreign body sensation (1% to 5%), itching of eye (1% to 5%), keratitis (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, alopecia, chest pain, conjunctivitis, diarrhea, diplopia, dizziness, dyspepsia, dyspnea, eye fatigue, hypertonia, keratoconjunctivitis, keratopathy, kidney pain, lid crusting, nausea, pharyngitis, tearing, urticaria, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F142328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to brinzolamide or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F142311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfonamide allergy: Brinzolamide is a sulfonamide; although administered ocularly, systemic absorption may occur and could result in hypersensitivity. Discontinue use if signs of hypersensitivity or a serious reaction occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute angle-closure glaucoma: Use has not been studied in acute angle-closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Corneal endothelium: Use with caution in patients with low endothelial cell counts; may be at increased risk of corneal edema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use is not recommended in patients with severe renal impairment (has not been studied).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral carbonic anhydrase inhibitors: Concurrent use with oral carbonic anhydrase inhibitors may result in additive systemic effects and is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Product contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F142361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F142316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of other Carbonic Anhydrase Inhibitors. The development of acid-base disorders with concurrent use of ophthalmic and oral carbonic anhydrase inhibitors has been reported. Management: Avoid concurrent use of different carbonic anhydrase inhibitors if possible.  Monitor patients closely for the occurrence of kidney stones and with regards to severity of metabolic acidosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F142318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F142330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F142346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13645977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F142329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Azopt Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (10 mL): $145.26",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F142320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F142331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Azopt (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, PY, RU, SE, SG, SK, SV, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Azoptic (ZA);",
"     </li>",
"     <li>",
"      BrinzoQuin (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F142310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Brinzolamide inhibits carbonic anhydrase, leading to decreased aqueous humor secretion. This results in a reduction of intraocular pressure.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F142327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Into systemic circulation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Accumulates extensively in red blood cells, binding to carbonic anhydrase (brinzolamide and metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To N-desethyl brinzolamide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8658 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-C88E1676B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29235=[""].join("\n");
var outline_f28_35_29235=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142340\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142341\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142366\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142343\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142344\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13646015\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682295\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142322\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142307\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142325\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142323\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142364\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142328\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142311\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142361\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142316\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142318\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142330\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142346\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13645977\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142329\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142320\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142331\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142310\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F142327\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8658\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8658|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/38/15972?source=related_link\">",
"      Brinzolamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_35_29236="Infected eczema hand";
var content_f28_35_29236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F74056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F74056&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Staphylococcus aureus infection in atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pustules and honey-colored crusting are seen on the dorsal hand of this patient with infected atopic dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Morelli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29236=[""].join("\n");
var outline_f28_35_29236=null;
var title_f28_35_29237="Flow cytometric analysis for MSMD";
var content_f28_35_29237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F69926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F69926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 656px\">",
"   <div class=\"ttl\">",
"    Flow cytometric analysis for Mendelian susceptibility to mycobacterial disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 636px; height: 419px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whole blood peripheral blood mononuclear cells (PBMCs) were stained with antibodies to interferon (IFN)-gamma receptor 1 or interleukin (IL)-12 receptor beta 1, respectively (top panels). Loss of these proteins is seen in Mendelian susceptibility to mycobacterial diseases (MSMD).",
"    <br>",
"     Bottom panels represent defective phosphorylation of signal transducer and activator of transcription (STAT) 1 in response to IFN-gamma (left) or STAT 4 in response to IL-12 (right).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29237=[""].join("\n");
var outline_f28_35_29237=null;
var title_f28_35_29238="Systemic lupus erythematosus (SLE)";
var content_f28_35_29238=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/35/29238/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/35/29238/contributors\" id=\"au5724\">",
"       Peter H Schur, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/35/29238/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/35/29238/contributors\" id=\"se5833\">",
"       Robert H Shmerling, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?28/35/29238/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/35/29238/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?28/35/29238?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SYSTEMIC LUPUS ERYTHEMATOSUS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Systemic lupus erythematosus (also known as lupus or SLE) is a chronic inflammatory disease that can affect various parts of the body. Lupus is an autoimmune condition, meaning that your body's immune system attacks your own tissues, thinking that they are foreign. This can lead to pain, swelling, and damage to organs such as the kidneys. The cause of lupus is not clear.",
"    </p>",
"    <p>",
"     People with lupus often have disease flares, in which symptoms worsen, followed by a period of remission, in which symptoms improve. Lupus is mild in some people and is life-threatening in others. However, treatments are available to reduce symptoms, to reverse inflammation, and to minimize organ damage.",
"    </p>",
"    <p>",
"     This article discusses the symptoms, diagnosis, and treatments for lupus in adults. The treatment of lupus in pregnant women is discussed in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36518?source=see_link\">",
"      \"Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      LUPUS CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The exact cause of lupus is not known. A person who develops lupus probably inherits the risk from one or both parents and then develops the disease when exposed to a trigger. Triggers may include being exposed to sunlight, being ill with an infection, having surgery, or being pregnant.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      SYMPTOMS OF SYSTEMIC LUPUS ERYTHEMATOSUS",
"     </span>",
"    </p>",
"    <p>",
"     Symptoms of lupus can be caused by inflammation, which can affect the whole or parts of the body. Other lupus symptoms are caused by inflammation",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     damage to a particular organ system.",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Whole body symptoms can include fatigue and weight loss.",
"      </li>",
"      <li>",
"       Organ-related symptoms include skin rash following sun exposure and easy bruising due to decreased numbers of platelets in the blood.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Whole body symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with lupus develop fatigue, fever, and weight loss at some point in their illness.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Fatigue",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fatigue is the most common symptom of lupus, and it is occasionally the most debilitating. Fatigue can occur in almost everyone, even when there are no other symptoms of lupus.",
"    </p>",
"    <p>",
"     Fatigue may be caused by lupus itself or by underlying issues, such as depression, unhealthy habits (smoking, unhealthy diet, drug abuse), stress, anemia, use of certain medications, underlying health problems, lack of exercise, and, in particular, difficulty sleeping.",
"    </p>",
"    <p>",
"     Problems with sleep are usually treated with medicine, and an exercise program can improve energy levels. (See",
"     <a class=\"local\" href=\"#H20\">",
"      'Exercise'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Weight changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Systemic lupus erythematosus can lead to both weight loss and weight gain. Unintentional weight loss is often due to:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Decreased appetite",
"      </li>",
"      <li>",
"       The side effects of medications",
"      </li>",
"      <li>",
"       Gastrointestinal disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Weight gain is usually due to one of two factors:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Salt and water retention associated with kidney disease (see",
"       <a class=\"local\" href=\"#H11\">",
"        'Kidneys'",
"       </a>",
"       below)",
"      </li>",
"      <li>",
"       Increased appetite associated with the use of glucocorticoids (steroids)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Fever",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with systemic lupus erythematosus have fevers. Fever is defined as a temperature over 100&deg;F (37.8&deg;C). Fever related to active lupus usually responds to nonsteroidal antiinflammatory drugs (NSAIDs) (eg, naproxen, ibuprofen)",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     acetaminophen. If fever does not improve with these treatments, call your healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Specific organ symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Systemic lupus erythematosus can affect many organs of the body and can result in a variety of symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Joint pain and stiffness",
"     </span>",
"     &nbsp;&mdash;&nbsp;Joint pain and stiffness occur in almost all patients with lupus, and these are often the earliest symptom of lupus. The pain and stiffness tends to move from one part of the body to another and does not usually affect both sides of the body in the same way. Only a few joints are affected at any time. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23753?source=see_link\">",
"      \"Musculoskeletal manifestations of systemic lupus erythematosus\"",
"     </a>",
"     .) Typical joints include the fingers, wrists, and knees. Joints may be swollen and warm (&ldquo;arthritis&rdquo;).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Skin changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with systemic lupus erythematosus have skin abnormalities at some time. The most common is a rash, known as the butterfly rash; this appears as redness over the cheeks and nose after being in the sun (",
"     <a class=\"graphic graphic_picture graphicRef79355 \" href=\"UTD.htm?29/40/30339\">",
"      picture 1",
"     </a>",
"     ). The rash usually lasts only a few days but often comes back. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link\">",
"      \"Mucocutaneous manifestations of systemic lupus erythematosus\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some people develop circular patches of raised, scaly skin (called discoid lesions), which have a tendency to scar (",
"     <a class=\"graphic graphic_picture graphicRef56910 \" href=\"UTD.htm?21/34/22054\">",
"      picture 2",
"     </a>",
"     ). Hair loss (alopecia) is common, but baldness is not. Many people develop ulcers in the mouth, which are usually painless.",
"    </p>",
"    <p>",
"     The Raynaud phenomenon causes blood vessels in the fingers and toes to narrow in response to cold temperatures, emotional stress, cigarette smoking,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     caffeine (",
"     <a class=\"graphic graphic_figure graphicRef71633 \" href=\"UTD.htm?0/36/583\">",
"      figure 1",
"     </a>",
"     ). As the blood vessels narrow, less blood flows to the area, causing the fingers or toes to become pale and then blue, purple,",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     red. Raynaud is a frequent problem in patients with systemic lupus erythematosus. However, most people who have Raynaud do not have lupus. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30481?source=see_link\">",
"      \"Patient information: Raynaud phenomenon (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Light sensitivity &mdash; Between 60 and 100 percent of people with lupus are sensitive to ultraviolet light. This &ldquo;photosensitivity&rdquo; causes the person to develop a rash after exposure to ultraviolet light from the sun or fluorescent lights. Some people are also sensitive to UVA radiation (from sunlight). Glass protects individuals sensitive to UVB (from sunlight or fluorescent light) but only partially protects those sensitive to UVA. Blonde, blue-eyed, fair-skinned individuals are much more photosensitive than brunettes or individuals with darker skin.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Those who are photosensitive should do the following to minimize UV exposure:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Avoid areas of high sun exposure (beaches, snow, lakes), especially between 10 AM and 3 PM.",
"      </li>",
"      <li>",
"       Avoid medications that may cause photosensitivity.",
"      </li>",
"      <li>",
"       Use a sunscreen with a sun-protection factor (SPF) of 50 or greater daily. The sunscreen should be applied 30 to 60 minutes before going outside and should be reapplied every four to six hours.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     More information about ways to minimize UV exposure is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"      \"Patient information: Sunburn prevention (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Kidneys",
"     </span>",
"     &nbsp;&mdash;&nbsp;Changes in kidney function are common in people with lupus. These changes usually develop during the first few years of the illness. Monitoring for changes in kidney function with urine and blood tests can help to detect these changes.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Lupus can cause inflammation of the filtering device in the kidneys (the glomerulus); this is called glomerulonephritis or lupus nephritis. Damage to the glomeruli can prevent the kidneys from filtering wastes from the bloodstream. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=see_link\">",
"        \"Patient information: Glomerular disease overview (Beyond the Basics)\"",
"       </a>",
"       and",
"       <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"        \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Initially, the kidneys may &ldquo;leak&rdquo; protein from the blood into the urine. When severe, this can cause water retention, swelling in the feet and lower legs, and other changes referred to as the nephrotic syndrome. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?35/2/35875?source=see_link\">",
"        \"Patient information: The nephrotic syndrome (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Left untreated, lupus nephritis can lead to permanent scarring in the kidneys. If the kidneys are too damaged to filter the blood properly, you will need dialysis or a kidney transplant. Fortunately, treatments to prevent or minimize lupus-related kidney disease are available.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Digestive system",
"     </span>",
"     &nbsp;&mdash;&nbsp;The digestive system can be affected by medications often used to treat lupus, including glucocorticoids and NSAIDs. These medicines can cause upset stomach, or less commonly, stomach ulcers. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     However, severe abdominal pain, nausea, and vomiting can occur if lupus affects the pancreas (pancreatitis), the lining of the abdomen (peritonitis), or the large intestine (colitis).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Lungs",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of lung diseases can occur in people with lupus (see",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=see_link\">",
"      \"Pulmonary manifestations of systemic lupus erythematosus in adults\"",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Pain with breathing &mdash; Pleurisy is a type of chest pain that is worsened by taking a deep breath. Pleurisy can occur if there is inflammation of the lining covering the lungs and inside of the chest.",
"      </li>",
"      <li>",
"       Shortness of breath &mdash; Shortness of breath can occur due to several different problems. Collection of fluid in the space around the lungs (called pleural effusion) can interfere with expansion of the lung. Inflammation of the air sacs of the lung (pneumonitis) or dysfunction and scarring of the supporting tissues between the air sacs (interstitial lung disease) can cause difficulty breathing.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Heart",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are a variety of symptoms that can develop if lupus affects the heart or blood vessels:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Chest pain with exercise &mdash; As mentioned above, people with lupus can develop chest pain as a result of pleurisy. In addition, lupus can increase the risk of developing coronary artery disease. Symptoms of coronary artery disease can include chest pain with exercise or emotional stress that resolves with rest (angina pectoris). Sudden severe chest pain or pressure that does not go away within a few minutes may be a sign of a heart attack (myocardial infarction).",
"      </li>",
"      <li>",
"       Chest pain due inflammation around the heart &mdash; Chest pain can also occur if lupus causes inflammation of the sac that surrounds the heart, a condition known as pericarditis.",
"      </li>",
"      <li>",
"       Shortness of breath due to heart valve disease &mdash; Shortness of breath can be caused by heart as well as lung involvement. The heart valves can become leaky or narrowed as a result of damage to the lining of the heart cavity and surfaces of the normally smooth valves (endocardium).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Nervous system",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lupus can affect the nervous system in many ways. These problems may be related to lupus itself, to treatments used for lupus, or to unknown causes. Some of the most common problems affecting the nervous system include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Difficulty concentrating and thinking clearly",
"      </li>",
"      <li>",
"       Confusion or memory loss",
"      </li>",
"      <li>",
"       Depression and anxiety",
"      </li>",
"      <li>",
"       Headaches",
"      </li>",
"      <li>",
"       Seizures",
"      </li>",
"      <li>",
"       Pain in the hands or feet (called peripheral neuropathy)",
"      </li>",
"      <li>",
"       Weakness or numbness",
"      </li>",
"      <li>",
"       Stroke (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?37/37/38484?source=see_link\">",
"        \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Treatments are available for lupus-related nervous system problems. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33978?source=see_link\">",
"      \"Neurologic manifestations of systemic lupus erythematosus\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38631?source=see_link\">",
"      \"Neuropsychiatric manifestations of systemic lupus erythematosus\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Eye",
"     </span>",
"     &nbsp;&mdash;&nbsp;The eye is sometimes affected by lupus. The most common symptom is dryness of the eyes with a feeling of grittiness or a lack of tearing (called keratoconjunctivitis sicca). This can be treated by using artificial tears.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      SYSTEMIC LUPUS ERYTHEMATOSUS DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The American College of Rheumatology has created criteria to classify patients with systemic lupus erythematosus. While these criteria were developed to aid in research, they are often used in medical practice to help with the diagnostic process. These criteria are shown in the table (",
"     <a class=\"graphic graphic_table graphicRef71430 \" href=\"UTD.htm?37/25/38300\">",
"      table 1",
"     </a>",
"     ) [",
"     <a class=\"abstract\" href=\"UTD.htm?28/35/29238/abstract/1\">",
"      1",
"     </a>",
"     ]. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"      \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Although there is no cure for lupus, a variety of treatments can reduce symptoms, can limit damage to vital organs, and can reduce the risk of recurrence.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Diet and nutrition",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people with lupus do not require a special diet but should instead eat a well-balanced diet. A well-balanced diet is one that is low in fat; that is high in fruits, vegetables, and whole grains; and that contains a moderate amount of meat, poultry, and fish.",
"    </p>",
"    <p>",
"     However, you may need to make changes to your diet, depending upon how lupus has affected your body. If you have questions about your diet, discuss these with your healthcare provider. In general:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       People with active lupus and fever may require more calories.",
"      </li>",
"      <li>",
"       Glucocorticoids (prednisone) increase appetite, potentially causing you to gain a lot of weight. Try to control your appetite and to stay active. Weigh yourself daily while taking prednisone, and talk to your healthcare provider if you gain more than 5 pounds.",
"      </li>",
"      <li>",
"       If your cholesterol or triglyceride levels become elevated, you may be advised to eat a special diet. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"        \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       If you have swelling (edema) in your feet or lower legs, decrease the amount of salt and sodium in your diet. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"        \"Patient information: Low sodium diet (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Extra vitamins are rarely needed if you eat a balanced diet. If you are not able to eat a balanced diet or are dieting to lose weight, you should take a multivitamin.",
"      </li>",
"      <li>",
"       If you take glucocorticoids every day or are a postmenopausal woman, you should take 1000 to 1500 mg of calcium and 400 to 800 units of vitamin D per day to minimize bone loss. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"        \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Drinking a moderate amount of alcohol (one drink or less for women and two drinks or less per day for men) is usually safe for people with lupus. However, alcohol can interact with medications used to treat lupus. Talk to your healthcare provider if you have questions.",
"      </li>",
"      <li>",
"       Herbal and other dietary supplements are not recommended and may even cause harm.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Being inactive while ill can cause you to lose muscle and energy quickly. A separate article discusses how to incorporate exercise into your life. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=see_link\">",
"      \"Patient information: Arthritis and exercise (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Immunizations",
"     </span>",
"     &nbsp;&mdash;&nbsp;Vaccines to prevent pneumonia and the flu are recommended for people with lupus.",
"    </p>",
"    <p>",
"     In contrast, vaccines that contain live viruses (eg, measles, mumps, rubella, polio, varicella, and smallpox) are not recommended for people with lupus, especially if you currently take prednisone. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"      \"Patient information: Adult vaccines (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Medication precautions",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of medications are known to worsen lupus. You should not take these medications if there is an acceptable alternative. Sulfa-containing antibiotics are examples of medicines that should be avoided.",
"    </p>",
"    <p>",
"     Birth control pills that contain low doses of estrogen (which include most birth control pills) are safe for most women with systemic lupus erythematosus. However, certain people (eg, those with Raynaud phenomenon, an increased risk of blood clots, or kidney disease) probably should not take any medicines that contain estrogen. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16646?source=see_link\">",
"      \"Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with lupus should avoid becoming pregnant during lupus flares due to the high risk of miscarriage. This is especially true in women with significant lupus-related organ damage.",
"    </p>",
"    <p>",
"     The chances of having an uncomplicated pregnancy and healthy newborn are improved by waiting to become pregnant until lupus has been under control for at least six months. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36518?source=see_link\">",
"      \"Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Treatment of specific organs",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of medications are commonly used in the treatment of lupus, including nonsteroidal antiinflammatory drugs (NSAIDs), antimalarials, glucocorticoids, and immunosuppressive agents.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h3\">",
"      Joint pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;A group of medicines, called nonsteroidal antiinflammatory drugs (NSAIDs) can usually relieve joint pain caused by lupus-related arthritis and inflammation. NSAIDs include ibuprofen (Advil&reg;, Motrin&reg;) or naproxen (Aleve&reg;, Naprosyn&reg;).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h3\">",
"      Skin symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antimalarial medications were originally designed as treatments for malaria but were found to be useful for people with lupus. An example of an antimalarial drug is hydroxychloroquine (Plaquenil&reg;). Antimalarials may be especially helpful for people with skin symptoms and joint pain that have not fully responded to NSAIDs. Antimalarial therapy may also help to protect the body from lupus-related organ damage [",
"     <a class=\"abstract\" href=\"UTD.htm?28/35/29238/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H27\">",
"     <span class=\"h3\">",
"      Glucocorticoids and immunosuppressives",
"     </span>",
"     &nbsp;&mdash;&nbsp;Glucocorticoids (also called steroids) may be used alone or in combination with medications that suppress the immune system (called immunosuppressive medicines). Examples of immunosuppressive medicines include mycophenolate, cyclophosphamide, azathioprine, and belimumab. These treatments are generally reserved for people with significant organ damage, particularly of the kidneys, blood, lungs, or nervous system, or for those needing high doses of glucocorticoids to treat their condition.",
"    </p>",
"    <p>",
"     The benefit of glucocorticoids and immunosuppressive medications must be weighed against the risks because these treatments have potentially serious side effects. Glucocorticoids can cause weight gain, worsened diabetes, thinning of bones (osteopenia and osteoporosis), and an increased risk of infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h3\">",
"      Other options",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of other treatment approaches for lupus have been tried or are under investigation. These include stem cell transplantation (bone marrow transplantation), anti-B cell antibodies (including rituximab and epratuzumab), and others.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H29\">",
"     <span class=\"h1\">",
"      HOW WILL SYSTEMIC LUPUS ERYTHEMATOSUS AFFECT MY LIFE?",
"     </span>",
"    </p>",
"    <p>",
"     Lupus can cause a wide spectrum of symptoms; in some people, it is relatively mild while, in others, it is a severe, debilitating illness.",
"    </p>",
"    <p>",
"     The survival rate of people with systemic lupus erythematosus has dramatically increased over the last several decades from approximately 40 percent still alive at five years in the 1950s to current survival rates of approximately 90 percent at 10 years. The improvement in survival is probably due to multiple factors, including the ability to recognize the disease earlier with more sensitive diagnostic tests, to begin treatment earlier, and to promptly treat complications.",
"    </p>",
"    <p>",
"     Many people go into remission and require no treatment. In one study, approximately 25 percent of patients had remission lasting for at least a year. Remission occurred in 50 percent of those with disease over 18 years&rsquo; duration and in 75 percent of those with disease over 30 years&rsquo; duration. Remission was even seen in some patients who had had severe kidney disease [",
"     <a class=\"abstract\" href=\"UTD.htm?28/35/29238/abstract/3\">",
"      3",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H30\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Researchers are continually conducting clinical trials of lupus treatments to find better ways of treating the disease. A clinical trial is a carefully controlled way to study the effectiveness of new treatments or new combinations of known therapies. For more information about clinical trials, visit",
"     <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"      file://clinicaltrials.gov",
"     </a>",
"     or",
"     <a class=\"external\" href=\"file://clinicalstudies.info.nih.gov/\">",
"      file://clinicalstudies.info.nih.gov",
"     </a>",
"     .",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H31\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7378361\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7378368\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/42/22178?source=see_link\">",
"      Patient information: Lupus (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/30/7651?source=see_link\">",
"      Patient information: Lupus and pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/56/11138?source=see_link\">",
"      Patient information: Pericarditis in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/49/36626?source=see_link\">",
"      Patient information: Lupus and kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/8/30850?source=see_link\">",
"      Patient information: Antinuclear antibodies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/21/26962?source=see_link\">",
"      Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/9/14483?source=see_link\">",
"      Patient information: Interstitial lung disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/5/16466?source=see_link\">",
"      Patient information: Discoid lupus (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7378392\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"     <br/>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/42/36518?source=see_link\">",
"      Patient information: Systemic lupus erythematosus and pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30481?source=see_link\">",
"      Patient information: Raynaud phenomenon (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/60/33729?source=see_link\">",
"      Patient information: Sunburn prevention (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/35/37426?source=see_link\">",
"      Patient information: Glomerular disease overview (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/2/35875?source=see_link\">",
"      Patient information: The nephrotic syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/61/39890?source=see_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=see_link\">",
"      Patient information: Arthritis and exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7378407\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=see_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29831?source=see_link\">",
"      Approach to the patient with macular skin lesions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44233?source=see_link\">",
"      Clinical features and therapy of membranous lupus nephritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/13/28889?source=see_link\">",
"      Coronary heart disease in systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/43/5816?source=see_link\">",
"      Diagnostic approach to the neuropsychiatric manifestations of systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/32/28168?source=see_link\">",
"      Drug-induced lupus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39352?source=see_link\">",
"      End-stage renal disease due to lupus nephritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=see_link\">",
"      Epidemiology and pathogenesis of systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/50/5928?source=see_link\">",
"      Gastrointestinal manifestations of systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16646?source=see_link\">",
"      Menstrual function, menopause, and hormonal contraceptives in women with systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23753?source=see_link\">",
"      Musculoskeletal manifestations of systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"      Neonatal lupus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33978?source=see_link\">",
"      Neurologic manifestations of systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38631?source=see_link\">",
"      Neuropsychiatric manifestations of systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/59/22456?source=see_link\">",
"      Non-coronary cardiac manifestations of systemic lupus erythematosus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41464?source=see_link\">",
"      Overview of the clinical manifestations of systemic lupus erythematosus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/45/39641?source=see_link\">",
"      Pregnancy in women with systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=see_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/3/12345?source=see_link\">",
"      Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Disease",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"        www.niams.nih.gov",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of Rheumatology",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"        www.rheumatology.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Arthritis Foundation",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/\">",
"        www.arthritis.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Lupus Foundation of America",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.lupus.org/\">",
"        www.lupus.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       S.L.E. Lupus Foundation and the Lupus Research Institute",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.lupusny.org/\">",
"        www.lupusny.org",
"       </a>",
"       and",
"       <a class=\"external\" href=\"file://lupusresearchinstitute.org/\">",
"        lupusresearchinstitute.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Alliance for Lupus Research",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.lupusresearch.org/\">",
"        www.lupusresearch.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?28/35/29238/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 6, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?28/35/29238?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29238/abstract/1\">",
"      Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29238/abstract/2\">",
"      Fessler BJ, Alarc&oacute;n GS, McGwin G Jr, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005; 52:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29238/abstract/3\">",
"      Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005; 32:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29238/abstract/4\">",
"      Chambers SA, Rahman A, Isenberg DA. Treatment adherence and clinical outcome in systemic lupus erythematosus. Rheumatology (Oxford) 2007; 46:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29238/abstract/5\">",
"      Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54:2970.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f28_35_29238=[""].join("\n");
var outline_f28_35_29238=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SYSTEMIC LUPUS ERYTHEMATOSUS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           LUPUS CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           SYMPTOMS OF SYSTEMIC LUPUS ERYTHEMATOSUS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           SYSTEMIC LUPUS ERYTHEMATOSUS DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           SYSTEMIC LUPUS ERYTHEMATOSUS TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H29\">",
"           HOW WILL SYSTEMIC LUPUS ERYTHEMATOSUS AFFECT MY LIFE?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H30\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H31\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/36/583\" title=\"figure 1\">",
"           Acute Raynaud phenomenon PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/40/30339\" title=\"picture 1\">",
"           Butterfly rash PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/34/22054\" title=\"picture 2\">",
"           Discoid lupus PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?37/25/38300\" title=\"table 1\">",
"           ARA criteria for SLE PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f28_35_29239="Ruxolitinib: Drug information";
var content_f28_35_29239=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ruxolitinib: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/12/37060?source=see_link\">",
"    see \"Ruxolitinib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13376660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Jakafi&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14732981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Jakavi&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13374759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Janus Associated Kinase Inhibitor;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Tyrosine Kinase Inhibitor;",
"     </li>",
"     <li>",
"      Janus Associated Kinase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F13382600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Myelofibrosis:",
"     </b>",
"     Oral: Initial dose (based on platelet count, titrate dose thereafter based on efficacy and safety):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets &gt;200,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 20 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets 100,000-200,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 15 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets &gt;200,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 20 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets 100,000-200,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 15 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets 50,000-100,000/ mm",
"     <sup>",
"      3",
"     </sup>",
"     : Initial dose should not exceed 5 mg twice daily; titrate dose cautiously",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage modification based on response:",
"     </b>",
"     For insufficient response (with adequate platelet and neutrophil counts), may increase the dose in 5 mg twice daily increments to a maximum dose of 25 mg twice daily. Do not increase during initial 4 weeks and no more frequently than every 2 weeks.  Discontinue treatment after 6 months if no reduction in spleen size or no improvement in symptoms. When discontinuing for reasons other than thrombocytopenia, consider gradual tapering by ~5 mg twice daily per week.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Dose increases may be considered if meet all of the following situations:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - 	Failure to achieve either a 50% reduction (from baseline) in palpable spleen length or a 35% reduction (from baseline) in spleen volume (measured by CT or MRI)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Platelet count &gt;125,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     at 4 weeks (and never &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Absolute neutrophil count (ANC) &gt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment with concomitant strong CYP3A4 inhibitors:",
"     </b>",
"     Initial dose: 10 mg twice daily (if platelet count &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ); additional dose adjustments should be made with careful monitoring. Avoid concomitant use if platelet count &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13382599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-59 mL/minute and platelets &gt;150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-59 mL/minute and platelets 100,000-150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Initial dose: 10 mg twice daily; additional dose adjustments should be made with careful monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     15-59 mL/minute and platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     End-stage renal disease (ESRD) on dialysis and platelets 100,000-200,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Initial dose: 15 mg; administer subsequent doses after dialysis on dialysis days. Additional dose adjustments should be made with careful monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ESRD on dialysis and platelets &gt;200,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Initial dose: 20 mg; administer subsequent doses after dialysis on dialysis days. Additional dose adjustments should be made with careful monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ESRD not requiring dialysis: Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute and platelets &ge;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Initial dose: 10 mg twice daily; additional dose adjustments should be made with careful monitoring",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute and platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Avoid use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ESRD on dialysis and platelets 100,000-200,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Initial dose: 15 mg; administer subsequent doses after dialysis on dialysis days. Additional dose adjustments should be made with careful monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ESRD on dialysis and platelets &gt;200,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Initial dose: 20 mg; administer subsequent doses after dialysis on dialysis days. Additional dose adjustments should be made with careful monitoring.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13382598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hepatic impairment and platelets &gt;150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hepatic impairment and platelets 100,000-150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Initial dose: 10 mg twice daily; additional dose adjustments should be made with careful monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hepatic impairment and platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Avoid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hepatic impairment and platelets &gt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Initial dose: 10 mg twice daily; additional dose adjustments should be made with careful monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Hepatic impairment and platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Avoid use.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F13382628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage modification for treatment interruption:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     Platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Interrupt treatment; upon platelet recovery (to &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ), dosing may be restarted or increased based on the following platelet levels and",
"     <b>",
"      maximum allowable doses",
"     </b>",
"     (when restarting, begin with a dose that is at least 5 mg twice daily below the dose at treatment interruption):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets &ge;125,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 20 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets 100,000 to &lt;125,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 15 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets 75,000 to &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 10 mg twice daily for at least 2 weeks; may increase to 15 mg twice daily if stable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets 50,000 to &lt;75,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : 5 mg twice daily for at least 2 weeks; may increase to 10 mg twice daily if stable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Continue to withhold treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Long-term maintenance at 5 mg twice daily has not demonstrated responses; limit use of the dose level to patients where the benefits outweigh risks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or ANC &lt;500 mm",
"     <sup>",
"      3",
"     </sup>",
"     : Interrupt treatment; upon recovery of platelets to &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or ANC to &ge;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , dosing may be restarted at 5 mg twice daily and then gradually titrated based on blood cell counts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage reduction for thrombocytopenia:",
"     </b>",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <col width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <col align=\"center\" width=\"80\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"       </th>",
"       <th align=\"center\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Dose at Time of Thrombocytopenia",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"6\" valign=\"middle\">",
"        <p style=\"text-indent:-2em;margin-left:2em;\">",
"         <b>",
"          Note:",
"         </b>",
"         Long-term maintenance at 5 mg twice daily has not demonstrated responses; limit use of the dose level to patients where the benefits outweigh risks",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         25 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5 mg twice/day",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Platelet Count",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         New Dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         New Dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         New Dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         New Dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         New Dose",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         100,000 to  &lt;125,000/mm",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         15 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No change",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No change",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         75,000 to &lt;100,000/mm",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No change",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50,000 to &lt;75,000/mm",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         5 mg twice/day",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;50,000/mm",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold dose",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold dose",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F13375647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Jakafi&trade;: 5 mg, 10 mg, 15 mg, 20 mg, 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F13382561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F13382560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Available through specialty/network pharmacies. Further information may be obtained from the manufacturer, Incyte, at 1-855-452-5234 or at www.Jakafi.com.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13382602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered orally with or without food. If a dose is missed, return to the usual dosing schedule and do",
"     <b>",
"      not",
"     </b>",
"     administer an additional dose.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     If unable to ingest tablets, may administer through a nasogastric (NG) tube (&ge;8 Fr): Suspend 1 tablet in ~40 mL water and stir for ~10 minutes and administer (within 6 hours after dispersion) with appropriate syringe; rinse NG tube with ~75 mL water (effect of enteral tube feeding on ruxolitinib exposure has not been evaluated)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13374761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13382558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ruxolitinib may be confused with ponatinib, riTUXimab",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13382580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (15% to 18%), headache (10% to 15%), insomnia (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Bruising (19% to 23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Cholesterol increased (17%; grade 2: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (23%), constipation (13%), nausea (13%), vomiting (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Anemia (96%; grade 3: 34%; grade 4: 11%), thrombocytopenia (70%; grade 3: 9%; grade 4: 4%), neutropenia (19%; grade 3: 5%; grade 4: 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (25%; grades 2/3: 2%), AST increased (17%; grade 2: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Dyspnea (16%), nasopharyngitis (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Flatulence (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary tract infection (9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Herpes zoster infection (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Cardiac murmur, edema, peripheral neuropathy, withdrawal syndrome (acute relapse of myelofibrosis symptoms, splenomegaly, worsening cytopenias, hemodynamic compensation, and septic shock-like syndrome)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13382566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s U.S. labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to ruxolitinib or any component of the formulation or container",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13382567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular: Use with caution in patients with a history of bradycardia, conduction disturbances, ischemic heart disease, heart failure and/or receiving other drugs that also affect heart rate/conduction; decreased heart rate (mean change 6-8 bpm) and prolongation of the PR interval (mean change 6-9 msec) and of the QT interval (mean 4-5 msec) were observed during some clinical trials. Canadian labeling recommends obtaining an ECG at baseline and then periodically during therapy; monitor heart rate and blood pressure during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hematologic toxicity: Hematologic toxicity, including thrombocytopenia, anemia and neutropenia may occur; may require dosage modification. Monitor complete blood counts. Patients with baseline platelets &lt;200,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     are more likely to develop thrombocytopenia during treatment. Thrombocytopenia is generally reversible with treatment interruption or dose reduction; platelet transfusions may be administered during treatment if clinically indicated. Anemia may require blood transfusion; may consider dose modification. Neutropenia (ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) is generally reversible and managed by treatment interruption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Infection: Assess for risk of developing serious bacterial, mycobacterial, fungal, or viral infection. Active serious infections should be resolved prior to treatment initiation. Monitor for infections during treatment. Prompt treatment is recommended if symptoms of herpes zoster infection develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: May require initial dosage reduction; avoid use if platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and with hepatic impairment (any degree).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: May require initial dosage reduction; avoid use if platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and with moderate-to-severe renal impairment or in patients with ESRD not requiring dialysis. Ruxolitinib is not removed by dialysis; however, some active metabolites may be removed. On dialysis days, patients are advised to take their dose following dialysis sessions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CYP3A4 mediated interactions: Reduced initial doses are recommended with concomitant use of strong CYP3A4 inhibitors (eg, clarithromycin, conivaptin, itraconazole, ketoconazole, nefazodone, posaconazole, protease inhibitors, telithromycin, voriconazole, grapefruit juice); if platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , avoid concomitant use with strong CYP3A4 inhibitors. No adjustment is recommended with concomitant use of mild or moderate CYP3A4 inhibitors or with CYP3A4 inducers (monitor closely for efficacy and titrate dose appropriately).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: Discontinue treatment after 6 months if no reduction in spleen size or no improvement in symptoms. Consider gradually tapering off if discontinuing for reasons other than thrombocytopenia. Within ~1 week after discontinuation, symptoms of myelofibrosis generally return to pretreatment levels.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Withdrawal syndrome: Acute relapse of myelofibrosis symptoms, splenomegaly, worsening cytopenias, hemodynamic compensation, and septic shock-like syndrome have been reported with treatment discontinuation (Tefferi, 2011). Consider gradually tapering off if discontinuing for reasons other than thrombocytopenia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13382922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F13382921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ruxolitinib. Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Ruxolitinib. Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving grapefruit juice whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F13382584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Avoid grapefruit juice (may increase the effects of ruxolitinib).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F13382562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13382563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased resorptions (late) and reduced fetal weights were observed in animal reproduction studies. Use during human pregnancy only if the potential treatment benefits outweigh risks.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13382564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/ not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13382565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13382601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with or without food.  Avoid grapefruit juice (may increase the effects of ruxolitinib).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Jakafi Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (60): $9156.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (60): $9156.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (60): $9156.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (60): $9156.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (60): $9156.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13382604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC (baseline, every 2-4 weeks until dose stabilized, then as clinically indicated), renal function, hepatic function. Canadian labeling recommends obtaining an ECG at baseline and then periodically during therapy; monitor heart rate and blood pressure during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13382587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Kinase inhibitor which selectively inhibits Janus Associated Kinases (JAKs), JAK1 and JAK2.  JAK1 and JAK2 mediate signaling of cytokine and growth factors responsible for hematopoiesis and immune function; JAK mediated signaling involves recruitment of STATs (signal transducers and activators of transcription) to cytokine receptors which leads to modulation of gene expression. In myelofibrosis, JAK1/2 activity is dysregulated; ruxolitinib modulates the affected JAK1/2 activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13382589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 53-65 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~97%; primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic, primarily via CYP3A4; forms active metabolites responsible for 20% to 50% of activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Ruxolitinib: 2.8-3 hours (hepatic impairment: 5 hours); Ruxolitinib + metabolites: ~6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (74%, &lt;1% as unchanged drug); feces (22%, &lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Harrison C, Kiladjian JJ, Al-Ali HK, et al, &ldquo;JAK Inhibition With Ruxolitinib versus Best Available Therapy for Myelofibrosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(9):787-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/35/29239/abstract-text/22375970/pubmed\" id=\"22375970\" target=\"_blank\">",
"        22375970",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mesa RA, Kantarjian H, Tefferi A, et al, &ldquo;Evaluating the Serial Use of the Myelofibrosis Symptom Assessment Form for Measuring Symptomatic Improvement: Performance in 87 Myelofibrosis Patients on a JAK1 and JAK2 Inhibitor (INCB018424) Clinical Trial,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2011, 117(21):4869-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/35/29239/abstract-text/21480207/pubmed\" id=\"21480207\" target=\"_blank\">",
"        21480207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shilling AD, Nedza FM, Emm T, et al, &ldquo;Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2010, 38(11):2023-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/35/29239/abstract-text/20699411/pubmed\" id=\"20699411\" target=\"_blank\">",
"        20699411",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tefferi A and Pardanani A, &ldquo;Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2011, 86(12):1188-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/35/29239/abstract-text/22034658/pubmed\" id=\"22034658\" target=\"_blank\">",
"        22034658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tefferi A, Litzow MR, and Pardanani A, Long-Term Outcome of Treatment With Ruxolitinib in Myelofibrosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(15):1455-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/35/29239/abstract-text/21995409/pubmed\" id=\"21995409\" target=\"_blank\">",
"        21995409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verstovsek S, Kantarjian H, Mesa RA, et al, &ldquo;Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2010, 363(12):1117-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/35/29239/abstract-text/20843246/pubmed\" id=\"20843246\" target=\"_blank\">",
"        20843246",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verstovsek S, Mesa RA, Gotlib J, et al, &ldquo;A Double Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(9):799-807.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/35/29239/abstract-text/22375971/pubmed\" id=\"22375971\" target=\"_blank\">",
"        22375971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17096 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-CC23815824-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29239=[""].join("\n");
var outline_f28_35_29239=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13376660\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14732981\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374759\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382600\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382599\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382598\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382628\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13375647\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382561\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382560\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382602\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374761\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382558\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382580\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382566\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382567\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382922\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382921\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382584\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382562\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382563\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382564\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382565\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382601\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322922\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382604\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382587\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13382589\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17096\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/17096|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/12/37060?source=related_link\">",
"      Ruxolitinib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_35_29240="Testosterone: Pediatric drug information";
var content_f28_35_29240=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Testosterone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?1/11/1209?source=see_link\">",
"    see \"Testosterone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/27/22966?source=see_link\">",
"    see \"Testosterone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9632723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F225996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Androderm&reg;;",
"     </li>",
"     <li>",
"      AndroGel&reg;;",
"     </li>",
"     <li>",
"      Axiron&reg;;",
"     </li>",
"     <li>",
"      Delatestryl&reg;;",
"     </li>",
"     <li>",
"      Depo&reg;-Testosterone;",
"     </li>",
"     <li>",
"      First&reg;-Testosterone;",
"     </li>",
"     <li>",
"      First&reg;-Testosterone MC;",
"     </li>",
"     <li>",
"      Fortesta&trade;;",
"     </li>",
"     <li>",
"      Striant&reg;;",
"     </li>",
"     <li>",
"      Testim&reg;;",
"     </li>",
"     <li>",
"      Testopel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Andriol&reg;;",
"     </li>",
"     <li>",
"      Androderm&reg;;",
"     </li>",
"     <li>",
"      AndroGel&reg;;",
"     </li>",
"     <li>",
"      Andropository;",
"     </li>",
"     <li>",
"      Delatestryl&reg;;",
"     </li>",
"     <li>",
"      Depotest&reg; 100;",
"     </li>",
"     <li>",
"      Everone&reg; 200;",
"     </li>",
"     <li>",
"      PMS-Testosterone;",
"     </li>",
"     <li>",
"      Testim&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Androgen",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/11/1209?source=see_link\">",
"      see \"Testosterone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children &ge;12 years, and Adolescents &lt;18 years:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage and duration of therapy depend upon age, sex, diagnosis, patient&rsquo;s response to therapy, and appearance of adverse effects; in general total doses &gt;400 mg/month are not required due to the prolonged action of the drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Delayed puberty:",
"     </b>",
"     Children &ge;12 years and Adolescents: Typically not recommended for use before 14 years of age (Palmert, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer labeling: Enanthate: 50-200 mg every 2-4 weeks; usual duration 4-6 months; various regimens evaluated, some begin with high initial doses and taper down as puberty progresses, and others begin low and titrate upward  to effect and then taper",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternate dosing: Initial: Enanthate or cypionate: 50 mg/dose every 4 weeks for 3-6 months; may increase dose in 25-50 mg increments for another 3-6 months to effect; maximum dose: 100 mg; typical duration of therapy: 12 months; if no response or inadequate response after 1 year of treatment, diagnosis should be reconsidered and 	additional testing performed (Palmert, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Subcutaneous implant: Pellet: Usual range: 150-450 mg every 3-6 months; usual duration: 4-6 months; dosing typically on the lower end of range; various regimens have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Male hypogonadism:",
"     </b>",
"     Children &ge;12  years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: Enanthate or cypionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initiation of pubertal growth: 25-75 mg every 3-4 weeks, gradually titrate dose every 6-9 months to 100-150 mg; typical duration of initiation therapy 3-4 years (Han, 2010; Wales, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance therapy: 200-250 mg every 3-4 weeks; once expected adult height and adequate virilization achieved, may convert to other testosterone replacement dosage form (eg, patch, gel, etc) (Han, 2010; Wales, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Subcutaneous implant: Pellet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Manufacturer&rsquo;s labeling: Usual range: 150-450 mg every 3-6 months; various regimens have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Alternate dosing: 8-10 mg/kg/dose every 6 months (Zacharin, 1997)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Multiple pituitary hormone deficiency (with microphallus):",
"     </b>",
"     Limited data available: Infants: I.M.: Enanthate or cypionate: 25 mg every 4 weeks for 1-3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents &ge;18 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Inoperable metastatic breast cancer (females):",
"     </b>",
"     I.M.: Enanthate: 200-400 mg every 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypogonadism or hypogonadotropic hypogonadism (males):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: Enanthate or cypionate: 50-400 mg every 2-4 weeks (FDA-approved dosing range); 75-100 mg/week or 150-200 mg every 2 weeks (Bhasin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Subcutaneous implant: Pellet: 150-450 mg every 3-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Buccal: 30 mg twice daily (every 12 hours) applied to the gum region above the incisor tooth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Gel: Apply to clean, dry, intact skin.",
"     <b>",
"      Do not apply testosterone gel to the genitals.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     AndroGel&reg; 1%: 50 mg  applied once daily  in the morning to the shoulder and upper arms or abdomen. Dosage may be increased to a maximum of 100 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Dose adjustment based on testosterone levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Less than normal range: Increase dose from 50 mg to 75 mg or from 75 mg to 100 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Greater than normal range: Decrease dose. Discontinue if consistently above normal at 50 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     AndroGel&reg; 1.62%: 40.5 mg applied once daily in the morning to the shoulder and upper arms. Dosage may be increased to a maximum of 81 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Dose adjustment based on testosterone levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     &gt;750 ng/dL: Decrease dose by 20.25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     350-750 ng/dL: Maintain current dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     &lt;350 ng/dL: Increase dose by 20.25 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Fortesta&trade;: 40 mg once daily in the morning. Apply to the thighs. Dosing range: 10-70 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Dose adjustment based on serum testosterone levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     &ge;2500 ng/dL: Decrease dose by 20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     1250 to &lt;2500 ng/dL: Decrease dose by 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     500 and &lt;1250 ng/dL: Maintain current dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     &lt;500 ng/dL: Increase dose by 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Testim&reg;: 5 g (containing 50 mg of testosterone) applied once daily (preferably in the morning) to the shoulder and upper arms. Dosage may be increased to a maximum of 10 g (containing 100 mg of testosterone) daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Dose adjustment based on testosterone levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Less than normal range: Increase dose from 5 g (50 mg testosterone) to 10 g (100 mg testosterone) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:14em;text-align:justify;\">",
"     Greater than normal range: Decrease dose. Discontinue if consistently above normal at 5 g (50 mg testosterone) daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Solution (Axiron&reg;): 60 mg once daily; dosage range: 30-120 mg/day. Apply to the axilla at the same time each morning; do not apply to other parts of the body. Apply to clean, dry, intact skin.",
"     <b>",
"      Do not apply testosterone solution to the genitals.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Dose adjustment based on serum testosterone levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &gt;1050 ng/dL: Decrease 60 mg/day dose to 30 mg/day; if levels &gt;1050 ng/dL persist after dose reduction discontinue therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &lt;300 ng/dL: Increase 60 mg/day dose to 90 mg/day, or increase 90 mg/day dose to 120 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Transdermal system (Androderm&reg;):",
"     <b>",
"      Note:",
"     </b>",
"     Initial dose is either 4 mg/day or 5 mg/day and dose adjustment varies as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Initial: 4 mg/day (as one 4 mg/day patch; do",
"     <b>",
"      not",
"     </b>",
"     use two 2 mg/day patches)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Dose adjustment based on testosterone levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &gt;930 ng/dL: Decrease dose to 2 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     400-930 ng/dL: Continue 4 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &lt;400 ng/dL: Increase dose to 6 mg/day (as one 4 mg/day and one 2 mg/day patch)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Initial: 5 mg/day (as one 5 mg/day or two 2.5 mg/day patches)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Dose adjustment based on testosterone levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &gt;1030 ng/dL: Decrease dose to 2.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     300-1030 ng/dL: Continue 5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     &lt;300 ng/dL: Increase dose to 7.5 mg/day (as one 5 mg/day and one 2.5 mg/day patch)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosing conversion:",
"      </i>",
"     </b>",
"     If needed, patients may be switched from the 2.5 mg/day, 5 mg/day, and 7.5 mg/day patches as follows. Patch change should occur at their next scheduled dosing. Measure early morning testosterone concentrations ~2 weeks after switching therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     From 2.5 mg/day patch to 2 mg/day patch",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     From 5 mg/day patch to 4 mg/day patch",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     From 7.5 mg/day patch to 6 mg/day patch (one 2 mg/day and one 4 mg/day patch)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Delayed puberty (males):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.M.: Enanthate: 50-200 mg every 2-4 weeks for a limited duration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pellet (for subcutaneous implantation): 150-450 mg every 3-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). Use with caution; may enhance edema formation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied). Use with caution; may enhance edema formation.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical [compounding kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     First&reg;-Testosterone MC: 2% (60 g) [contains benzyl alcohol, sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AndroGel&reg;: 1% [25 mg/packet] (30s); 1% [50 mg/packet] (30s); 1% [12.5 mg/actuation] (75 g); 1.62% [40.5 mg/packet] (30s); 1.62% [20.25 mg/actuation] (75 g); 1.62% [20.25 mg/packet] (30s) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fortesta&trade;: 10 mg/actuation (60 g) [contains ethanol; 0.5 g gel/actuation; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Testim&reg;: 1% [50 mg/tube] (30s) [contains ethanol 74%; may be chemically synthesized from soy]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Implant, subcutaneous:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Testopel&reg;: 75 mg (10s, 24s, 100s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil, as cypionate: 100 mg/mL (10 mL [DSC]); 200 mg/mL (1 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Depo&reg;-Testosterone: 100 mg/mL (10 mL); 200 mg/mL (1 mL, 10 mL) [contains benzyl alcohol, benzyl benzoate, cottonseed oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil, as enanthate: 200 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delatestryl&reg;: 200 mg/mL (5 mL) [contains chlorobutanol, sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mucoadhesive, for buccal application [buccal system]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Striant&reg;: 30 mg (60s) [may be chemically synthesized from soy]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical [compounding kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     First&reg;-Testosterone: 2% (60 g) [contains benzyl alcohol, sesame oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Androderm&reg;: 2 mg/24 hours (60s); 4 mg/24 hours (30s) [contains ethanol, metal]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for prescription compounding, as propionate: USP: 100% (25 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Axiron&reg;: 30 mg/actuation (110 mL) [contains ethanol, isopropyl alcohol; 60 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Injection, powder",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F226030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F9632804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AndroGel&reg; 1%:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM188474.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM188474.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AndroGel&reg; 1.62%:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM255313.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM255313.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Axiron&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249396.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249396.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fortesta&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM239932.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM239932.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Testim&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM188475.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM188475.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Testosterone Gel:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM294248.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM294248.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062471\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral, buccal: Striant&trade;: One mucoadhesive for buccal application (buccal system) should be applied to a comfortable area above the incisor tooth. Apply flat side of system on fingertip. Gently push the curved side against upper gum. Rotate to alternate sides of mouth with each application. Hold buccal system firmly in place for 30 seconds to ensure adhesion. The buccal system should adhere to gum for 12 hours. If the buccal system falls out, replace with a new system. If the system falls out within 4 hours of next dose, the new buccal system should remain in place until the time of the following scheduled dose. System will soften and mold to shape of gum as it absorbs moisture from mouth. Do not chew or swallow the buccal system; check to ensure buccal system is in place following toothbrushing, use of mouthwash, and consumption of food or beverages. The buccal system will not dissolve; gently remove by sliding downwards from gum; avoid scratching gum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: I.M. (cypionate, enanthate): Warming injection to room temperature and shaking vial will help redissolve crystals that have formed after storage. Administer by deep I.M. injection into the upper outer quadrant of the gluteus maximus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal patch: Androderm&reg;: Apply patch to clean, dry area of skin on the back, abdomen, upper arms, or thigh. Do not apply to bony areas or parts of the body that are subject to prolonged pressure while sleeping or sitting.",
"     <b>",
"      Do not apply to the scrotum.",
"     </b>",
"     Avoid showering, washing the site, or swimming for 3 hours after application. Following patch removal, mild skin irritation may be treated with OTC hydrocortisone cream. A small amount of triamcinolone acetonide 0.1% cream may be applied under the system to decrease irritation; do not use ointment. Patch should be applied nightly. Rotate administration sites, allowing 7 days between applying to the same site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topical gel and solution: Apply to clean, dry, intact skin. Application sites should be allowed to dry for a few minutes prior to dressing. Hands should be washed with soap and water after application.",
"     <b>",
"      Do not apply testosterone gel or solution to the genitals.",
"     </b>",
"     Alcohol-based gels and solutions are flammable; avoid fire or smoking until dry. Testosterone may be transferred to another person following skin-to-skin contact with the application site. Strict adherence to application instructions is needed in order to decrease secondary exposure. Thoroughly wash hands after application and cover application site with clothing (ie, shirt) once gel or solution has dried, or clean application site thoroughly with soap and water prior to contact in order to minimize transfer. In addition to skin-to-skin contact, secondary exposure has also been reported following exposure to secondary items (eg, towel, shirt, sheets). If secondary exposure occurs, the other person should thoroughly wash the skin with soap and water as soon as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AndroGel&reg; 1%, AndroGel&reg; 1.62%, Testim&reg;: Apply (preferably in the morning) to clean, dry, intact skin of the shoulder and upper arms. AndroGel&reg; 1% may also be applied to the abdomen; do not apply AndroGel&reg; 1.62% or Testim&reg; to the abdomen. Area of application should be limited to what will be covered by a short-sleeve t-shirt. Apply at the same time each day. Upon opening the packet(s), the entire contents should be squeezed into the palm of the hand and immediately applied to the application site(s). Alternatively, a portion may be squeezed onto palm of hand and applied, repeating the process until entire packet has been applied. Application site should not be washed for &ge;2 hours following application of AndroGel&reg; 1.62% or Testim&reg;, or &gt;5 hours for AndroGel&reg; 1%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AndroGel&reg; 1% multidose pump: Prime pump 3 times (and discard this portion of product) prior to initial use. Each actuation delivers 12.5 mg of testosterone (4 actuations = 50 mg; 6 actuations = 75 mg; 8 actuations = 100 mg); each actuation may be applied individually or all at the same time. Application site should not be washed for &gt;5 hours following application.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     AndroGel&reg; 1.62% multidose pump: Prime pump 3 times (and discard this portion of product) prior to initial use. Each actuation delivers 20.25 mg of gel (2 actuations = 40.5 mg; 3 actuations = 60.75 mg; 4 actuations = 81 mg); each actuation may be applied individually or all at the same time.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Axiron&reg;: Apply using the applicator to the axilla at the same time each morning. Do not apply to other parts of the body (eg,  abdomen, genitals, shoulders, upper arms). Avoid washing the site or swimming for 2 hours after application. Prior to first use, prime the applicator pump by depressing it 3 times (discard this portion of the product). After priming, position the nozzle over the applicator cup and depress pump fully one time; ensure liquid enters cup. Each pump actuation delivers testosterone 30 mg. No more than 30 mg (one pump) should be added to the cup at one time. The total dose should be divided between axilla (eg, 30 mg/day: Apply to one axilla only; 60 mg/day: Apply 30 mg to each axilla; 90 mg/day: Apply 30 mg to each axilla, allow to dry, then apply an additional 30 mg to one axilla; etc). To apply dose, keep applicator upright and wipe into the axilla; if solution runs or drips, use cup to wipe. Do not rub into skin with fingers or hand. If more than one 30 mg dose is needed, repeat process. Apply roll-on or stick antiperspirants or deodorants prior to testosterone. Once application site is dry, cover with clothing. After use, rinse applicator under running water and pat dry with a tissue. The application site and dose of this product are not interchangeable with other topical testosterone products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fortesta&trade;: Apply to skin of front and inner thighs. Do not apply to other parts of the body. Use one finger to rub gel evenly onto skin of each thigh. Avoid showering, washing the site, or swimming for 2 hours after application. Prior to first dose, prime the pump by holding canister upright and fully depressing the pump 8 times (discard this portion of the product). Each pump actuation delivers testosterone 10 mg. The total dose should be divided between thighs (eg, 10 mg/day: Apply 10 mg to one thigh only; 20 mg/day: Apply 10 mg to each thigh; 30 mg/day: Apply 20 mg to one thigh and 10 mg to the other thigh; etc). Once application site is dry, cover with clothing. The application site and dose of this product are not interchangeable with other topical testosterone products.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1062461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Androderm&reg;: Store at room temperature. Do not store outside of pouch; excessive heat may cause system to burst.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AndroGel&reg; 1%, AndroGel&reg; 1.62%, Axiron&reg;, Delatestryl&reg;, Striant&reg;, Testim&reg;: Store at room temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Depo&reg; Testosterone: Store at room temperature; protect from light.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fortesta&trade;: Store at room temperature; do not freeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Testopel&reg;: Store in a cool, dry location.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cypionate injection: Testosterone hormone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired) (All indications: FDA approved in ages &ge;12 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Enanthate injection:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Male patients: Testosterone hormone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired); delayed puberty (All indications: FDA approved in adolescents and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Female patients: Inoperable metastatic breast cancer (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pellet (subcutaneous implant): Testosterone hormone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired) (All indications: FDA approved in adolescents and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buccal  system, topical gel, topical solution, transdermal system: Testosterone hormone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone; primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism(congenital or acquired) (All indications: FDA approved in ages &ge;18 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F226035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Testosterone may be confused with testolactone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Testoderm may be confused with Estraderm&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       AndroGel&reg; 1% may be confused with AndroGel&reg; 1.62%",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Bio-T-Gel may be confused with T-Gel",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - weak).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F226034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Deep venous thrombosis, edema, hypertension, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, aggressive behavior, anger, amnesia, anxiety, blood pressure increased/decreased, chills, depression, dizziness, emotional lability, excitation, fatigue, headache, hostility, insomnia, malaise, memory loss, mood swings, nervousness, seizure, sleep apnea, sleeplessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, alopecia, contact dermatitis, dry skin, erythema, folliculitis, hair discoloration, hirsutism (increase in pubic hair growth), pruritus, rash, seborrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain/soreness, gonadotropin secretion decreased, growth acceleration, gynecomastia, hot flashes, hypercalcemia, hyperchloremia, hypercholesterolemia, hyper-/hypoglycemia, hyper-/hypokalemia, hyperlipidemia, hypernatremia, inorganic phosphate retention, libido changes, menstrual problems (including amenorrhea), virilism, water retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Appetite increased, diarrhea, gastroesophageal reflux, GI bleeding, GI irritation, nausea, taste disorder, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Following buccal administration (most common): Bitter taste, gum edema, gum or mouth irritation, gum pain, gum tenderness, taste perversion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder irritability, impotence, oligospermia, penile erections (spontaneous), priapism, prostatic carcinoma, prostatic hyperplasia, prostatitis, PSA increased, testicular atrophy, urination impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Bilirubin increased, cholestatic hepatitis, cholestatic jaundice, hepatic dysfunction, hepatic necrosis, hepatocellular neoplasms, liver function test changes, peliosis hepatis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding, hematocrit/hemoglobin increased, leukopenia, polycythemia, suppression of clotting factors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Application site reaction (gel, solution), injection site inflammation/pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal system: Allergic contact dermatitis to system, burning at application site, burn-like blisters under system; burning, erythema, exfoliation, induration, pruritus, and/or vesicles at application site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, hemarthrosis, hyperkinesias, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Creatinine increased, hematuria, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasopharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions, diaphoresis, hypersensitivity reactions, smell disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Injection: Cough, coughing fits, respiratory distress; migraine; virilization of children following secondary exposure to topical gel (advanced bone age, aggressive behavior, enlargement of clitoris requiring surgery, enlargement of penis, erections increased, libido increased, pubic hair development); vitreous detachment",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to testosterone or any component (see manufacturer labeling for specific information); males with known or suspected carcinoma of the breast or prostate; specific products are contraindicated in women (see manufacturer labeling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Depo&reg;-Testosterone: Serious renal, hepatic, or cardiac disease",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal or hepatic impairment) or medications that enhance edema formation (eg, corticosteroids); testosterone may cause fluid retention. Use with caution in obesity or chronic lung disease; may potentiate sleep apnea. Use with caution in diabetes; testosterone may alter insulin sensitivity and glycemic control; additionally, the anabolic activity of testosterone activity may enhance hypoglycemia. Use caution with history of MI or coronary artery disease; may alter lipid profile. Use with caution in cancer or immobile patients; may cause hypercalcemia associated with hypercalciuria; monitor serum calcium concentrations. May cause gynecomastia in male patients. Long-term effects on gum safety when using the buccal formulation are not available; instruct patients to regularly inspect gum region where buccal formulation has been applied.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . May accelerate bone maturation without producing compensating gain in linear growth; in prepubertal children perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers. Virilization in children has been reported following contact with unwashed or unclothed application sites of men using the topical testosterone",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; symptoms include advanced bone age, aggressive behavior, enlargement of clitoris requiring surgery, enlargement of penis, erections increased, libido increased, pubic hair development. Patients should strictly adhere to instructions for use in order to prevent secondary exposure. Virilization of female sexual partners has also been reported with male use of the topical testosterone. Symptoms of virilization generally regress following removal of exposure; however, some children did not fully return to age appropriate normal. Signs of inappropriate virilization in women or children following secondary exposure to topical testosterone  should be brought to the attention of a healthcare provider. In the event that unwashed or unclothed skin comes in direct contact with testosterone gel, wash with soap and water. In females being treated for metastatic breast cancer, virilization may occur; monitor for signs of virilization; discontinue if mild virilization is present to prevent irreversible symptoms. High initial doses may cause priapism in adolescent males.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Urethral obstruction may develop in patients with BPH; discontinue therapy if occurs; may increase risk of prostatic cancer; if restarted a lower dose should be used. Withhold therapy pending urological evaluation in patients with palpable prostate nodule or induration, PSA &gt;4 ng/mL, or PSA &gt;3 ng/mL in men at high risk of prostate cancer (Bhasin, 2010). Prolonged use of high doses of androgens has been associated with serious hepatic effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, jaundice). Prolonged use of intramuscular testosterone enanthate has been associated with multiple hepatic adenomas. May cause reversible increases in hematocrit (polycythemia) due to increases of red blood cell mass which may increase risk of thromboembolic events; monitor hematocrit at baseline, 3-6 months after initiation and then annually; discontinue therapy if hematocrit exceeds 54%; may require reinitiation at a lower dose (Bhasin, 2010).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some dosage forms (see manufacturer&rsquo;s labeling) contain benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites. Some testosterone products may be chemically synthesized from soy which may cause allergic reactions in susceptible individuals. May contain other excipients (eg, sesame oil cottonseed oil) which may cause allergic reactions in susceptible individuals (see manufacturer&rsquo;s labeling). Some products may contain ethanol (see manufacturer&rsquo;s labeling); patients should be instructed on appropriate storage and application precautions to avoid heat and flame. Fortesta&trade; is not interchangeable with other topical testosterone products. AndroGel&reg; 1% and AndroGel&reg; 1.62% are not interchangeable. Axiron&reg; is not interchangeable with other topical testosterone products; safety and efficacy of Axiron&reg; use in male patients with BMI &gt;35 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     has not been established. Transdermal patch may contain conducting metal (eg, aluminum) which may cause a burn to the skin during an MRI scan; remove patch prior to MRI; reapply patch after scan is completed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F226024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F15575834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Buccal system: Food and beverages have not been found to interfere; ensure system is in place following eating, drinking, or brushing teeth.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F225980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Testosterone may cause adverse effects, including masculinization of the female fetus, if used during pregnancy. Females who are or may become pregnant should also avoid skin-to-skin contact to areas where testosterone has been applied topically on another person.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic liver function tests, cholesterol, hemoglobin and hematocrit (prior to therapy, at 3-6 months, then annually); radiologic examination of wrist and hand every 6 months (when using in prepubertal children). Withhold initial treatment with hematocrit &gt;50%, hyperviscosity, untreated obstructive sleep apnea, or uncontrolled severe heart failure. Monitor urine and serum calcium and signs of virilization in women treated for breast cancer. Serum glucose (may be decreased by testosterone, monitor patients with diabetes). Evaluate males for response to treatment and adverse events 3-6 months after initiation and then annually.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bone mineral density: Monitor after 1-2 years of therapy in hypogonadal men with osteoporosis or low trauma fracture (Bhasin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     PSA: In men &gt;40 years of age with baseline PSA &gt;0.6 ng/mL, PSA and prostate exam (prior to therapy, at 3-6 months, then as based on current guidelines). Withhold treatment pending urological evaluation in patients with palpable prostate nodule or induration or PSA &gt;4 ng/mL or if PSA &gt;3 ng/mL in men at high risk of prostate cancer (Bhasin, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Do not treat with severe untreated BPH with IPSS symptom score &gt;19.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Serum testosterone: After initial dose titration (if applicable), monitor 3-6 months after initiating treatment, then annually",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Injection: Measure midway between injections. Adjust dose or frequency if testosterone concentration is &lt;400 ng/dL or &gt;700 ng/dL (Bhasin, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AndroGel&reg; 1%, Testim&reg;: Morning serum testosterone levels ~14 days after start of therapy or dose adjustments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     AndroGel&reg; 1.62%: Morning serum testosterone levels after 14 and 28 days of starting therapy or dose adjustments and periodically thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Androderm&reg;: Morning serum testosterone levels (following application the previous evening) ~14 days after start of therapy or dose adjustments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Axiron&reg;: Serum testosterone levels can be measured 2-8 hours after application and after 14 days of starting therapy or dose adjustments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fortesta&trade;: Serum testosterone levels can be measured 2 hours after application and after 14 and 35 days of starting therapy or dose adjustments",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Striant&reg;: Application area of gums; total serum testosterone 4-12 weeks after initiating treatment, prior to morning dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Testopel&reg;: Measure at the end of the dosing interval (Bhasin, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1062469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Total testosterone, males:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     12-13 years: &lt;800 ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     14 years: &lt;1200 ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     15-16 years: 100-1200 ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     17-18 years: 300-1200 ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     19-40 years: 300-950 ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;40 years: 240-950 ng/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Free testosterone, males: 9-30 ng/dL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Principal endogenous androgen responsible for promoting the growth and development of the male sex organs and maintaining secondary sex characteristics in androgen-deficient males",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1062473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration (route and ester dependent): Cypionate and enanthate esters (I.M. administration) have the longest duration: &le;2-4 weeks; pellets: 3-4 months; gel: 24-48 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Transdermal gel: ~10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%, bound to sex hormone-binding globulin (40%) and albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic; forms metabolites including estradiol and dihydrotestosterone (DHT); both are active",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Variable: 10-100 minutes; Cypionate: I.M.: 8 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (90%), feces (6%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1062463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/27/22966?source=see_link\">",
"      see \"Testosterone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should not be used in female patients except in rare situations. Drug can cause male-like features in females or children, such as changes in sex drive, increased body hair, acne, aggressive behavior, or irregular periods. It should be applied to clean, dry skin and then covered with clothing. No swimming or showering should be allowed up to &ge;2 hours (product-dependent) after topical application. Testosterone may lower blood sugars and symptoms of hypoglycemia, such as shaking, hunger, blurred vision, or rapid heartbeat, should be monitored. Inform prescriber if patient has history of diabetes or liver or kidney disease. Serious side effects which need to be reported include problems with urination, ankle swelling, nausea or stomach pains, or frequent or prolonged erections. If using buccal formulation, regularly inspect gum region where it is applied; gum irritation or tenderness should resolve in 1-14 days; notify healthcare provider if persists beyond this time.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bhasin S, Cunningham GR, Hayes FJ, et al, &ldquo;Testosterone Therapy in Men With Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2010, 95(6):2536-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/35/29240/abstract-text/20525905/pubmed\" id=\"20525905\" target=\"_blank\">",
"        20525905",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Han TS and Bouloux PM, \"What Is the Optimal Therapy for Young Males With Hypogonadotropic Hypogonadism?\"",
"      <i>",
"       Clin Endocrinol (Oxf)",
"      </i>",
"      , 2010, 72(6):731-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/35/29240/abstract-text/19912242/pubmed\" id=\"19912242\" target=\"_blank\">",
"        19912242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Palmert MR and Dunkel L, \"Clinical Practice. Delayed Puberty,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 366(5):443-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/35/29240/abstract-text/22296078/pubmed\" id=\"22296078\" target=\"_blank\">",
"        22296078",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wales JK, \"Disordered Pubertal Development,\"",
"      <i>",
"       Arch Dis Child Educ Pract Ed",
"      </i>",
"      , 2012, 97(1):9-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/35/29240/abstract-text/21278425/pubmed\" id=\"21278425\" target=\"_blank\">",
"        21278425",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zacharin MR and Warne GL, \"Treatment of Hypogonadal Adolescent Boys With Long Acting Subcutaneous Testosterone Pellets,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1997, 76(6):495-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/35/29240/abstract-text/9245845/pubmed\" id=\"9245845\" target=\"_blank\">",
"        9245845",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12827 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-2733C36ADC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29240=[""].join("\n");
var outline_f28_35_29240=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9632723\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225996\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225997\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062466\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062458\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225970\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225954\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226030\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9632804\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062471\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062461\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062470\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226035\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226034\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062475\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062457\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062456\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226024\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225962\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15575834\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225965\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225980\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062465\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062469\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062455\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062473\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062474\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062463\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12827\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12827|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/11/1209?source=related_link\">",
"      Testosterone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/27/22966?source=related_link\">",
"      Testosterone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_35_29241="Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment";
var content_f28_35_29241=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/35/29241/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/35/29241/contributors\">",
"     T. Scott Stroup, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/35/29241/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/35/29241/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/35/29241/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/35/29241/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/35/29241/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/35/29241/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16350450\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schizophrenia is a psychiatric disorder involving chronic or recurrent psychosis. It is commonly associated with impairments in social and occupational functioning [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/1\">",
"     1",
"    </a>",
"    ]. It is among the most disabling and economically catastrophic medical disorders, ranked by the World Health Organization as one of the top ten illnesses contributing to the global burden of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antipsychotic medications are first-line medication treatment for schizophrenia. They have been shown in clinical trials to be effective in treating symptoms and behaviors associated with the disorder. Antipsychotic medications have significant side effects; assessment and management of these adverse effects are an important part of treatment. Evidence-based psychosocial interventions in conjunction with pharmacotherapy can help patients achieve recovery.",
"   </p>",
"   <p>",
"    This topic addresses the pharmacotherapy of schizophrenia in acute and maintenance phase treatment. Discussed separately are the use of long-acting antipsychotics and management of side effects during pharmacotherapy for schizophrenia; the epidemiology, pathogenesis, clinical presentation, epidemiology, clinical manifestations, and diagnosis of schizophrenia: psychosocial interventions for schizophrenia; and common comorbid presentations of schizophrenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20057?source=see_link\">",
"     \"Schizophrenia: Epidemiology and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8904?source=see_link\">",
"     \"Psychosocial interventions for schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2105?source=see_link\">",
"     \"Anxiety in schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25944?source=see_link\">",
"     \"Depression in schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=see_link\">",
"     \"Dual diagnosis: Severe mental illness and substance use disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=see_link\">",
"     \"Guidelines for prescribing clozapine in schizophrenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16350597\">",
"    <span class=\"h1\">",
"     ACUTE PHASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The focus of treatment in schizophrenia changes as individuals enter different phases of the illness. An acute phase occurs when patients with a prior history of schizophrenia have a psychotic relapse or during the first episode of psychosis. At this time, the focus is on reducing the severity of psychotic thoughts and behaviors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link&amp;anchor=H17284539#H17284539\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956391942\">",
"    <span class=\"h2\">",
"     Pre-treatment assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When feasible, patients who are started on an antipsychotic medication should receive a baseline physical examination with a neurological exam. Particular attention should be focused on factors that may be affected adversely by antipsychotic medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Body mass index (BMI)",
"     </li>",
"     <li>",
"      Waist circumference",
"     </li>",
"     <li>",
"      Heart rate",
"     </li>",
"     <li>",
"      Blood pressure",
"     </li>",
"     <li>",
"      Signs of a movement disorder:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Extrapyramidal symptoms (EPS): akathisia, parkinsonism, dystonias",
"     </li>",
"     <li>",
"      Tardive dyskinesia: abnormal movements of the face, peri-oral areas, tongue, extremities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When feasible, laboratory evaluations should be initiated before starting an antipsychotic. With the exception of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , the antipsychotic can usually be started before the results of laboratory tests are available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CBC, electrolytes, fasting glucose, lipid profile, liver, renal and thyroid function tests",
"     </li>",
"     <li>",
"      White blood cell (WBC) count with differential for patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"     </li>",
"     <li>",
"      ECG for patients with a cardiac history or those being treated with antipsychotics that may prolong the QT interval such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"       thioridazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/59/35767?source=see_link\">",
"       iloperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2758642\">",
"    <span class=\"h2\">",
"     Antipsychotic drug efficacy and selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antipsychotic drugs are first-line treatment for schizophrenia. Randomized trials have shown that antipsychotics reduce positive symptoms of schizophrenia, such as hallucinations, delusions, and suspiciousness, compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/3\">",
"     3",
"    </a>",
"    ]. Antipsychotics eliminate or reduce these symptoms to a tolerable level in about 70 percent of patients with schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With the exception of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , careful systematic reviews and meta-analyses have not found convincing evidence that any of the antipsychotics are more effective than any other for acute schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/5\">",
"     5",
"    </a>",
"    ]. Clozapine is more effective for patients who do not respond fully to other antipsychotics but due to increased risk of agranulocytosis is reserved for those who do not respond well to or cannot tolerate other antipsychotics. (See",
"    <a class=\"local\" href=\"#H108920615\">",
"     'Clozapine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are important differences among the antipsychotics in areas other than efficacy, including side effects and available formulations (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ). As a result, the selection of an antipsychotic is often based on these considerations. The selection may vary for select populations including individuals in a first psychotic episode, individuals who are only partial responders to antipsychotics, patients who are agitated, and individuals who are sensitive to particular side effects such as weight gain, EPS, or sedation. (See",
"    <a class=\"local\" href=\"#H16350492\">",
"     'Management of refractory symptoms'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16350527\">",
"     'Managing first episodes'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18522653\">",
"     'Management of agitation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13510771\">",
"    <span class=\"h3\">",
"     Antipsychotic drug categories",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antipsychotic medications are commonly grouped into two categories, with &ldquo;second-generation&rdquo; (or &ldquo;atypical&rdquo;) applied to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and all antipsychotics first marketed after clozapine was approved in 1989, and &ldquo;first-generation&rdquo; applied to antipsychotics marketed previously. Recent clinical research, however, has strongly suggested that the distinction between first- and second-generation antipsychotics has questionable validity and is confusing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/5\">",
"     5",
"    </a>",
"    ]. The pharmacologic properties, therapeutic effects, and adverse effects are not distinct between and are heterogeneous within the groups. Nevertheless, the terms first and second-generation antipsychotic are still in widespread use. A valid distinction is that the newer (second-generation) antipsychotics tend to cause fewer extrapyramidal side effects than the older ones, particularly at the high end of approved dosage ranges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16350464\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of most antipsychotic drugs should be titrated from an initial dose to the therapeutic range as quickly as tolerated.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     Quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/59/35767?source=see_link\">",
"     iloperidone",
"    </a>",
"    need to be increased gradually before reaching a therapeutic dose. The timeframe for titration differs for each drug and also depends on the individual patient&rsquo;s tolerance of the drug&rsquo;s tendency to cause sedation and hypotension. In most cases, patients can reach a therapeutic level in five or six days with quetiapine and iloperidone, and two to three weeks with clozapine. Suggested dosing and side effect profiles for each antipsychotic drug are shown in tables (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Because identifying the appropriate dose range can be difficult in the pre-marketing phases of drug development, the antipsychotic doses listed (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ) deviate somewhat from those approved by the US Food and Drug Administration, reflecting more recent research findings or clinical experience. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       Haloperidol",
"      </a>",
"      is effective and most useful at doses drastically below the FDA-specified maximum of 100",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Optimal haloperidol dosages are usually below 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      and almost always below 20",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      Optimal dosages of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      are lower than the approved 16",
"      <span class=\"nowrap\">",
"       mg/day;",
"      </span>",
"      typically, a maximum dose for risperidone is 6 to 8",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Resolution of psychotic symptoms generally occurs over several days and may take as much as four to six weeks. Clinicians should avoid the impulse to change the medication or dose prematurely. Once the dose reaches the therapeutic range, the decision to increase the dose should follow at least several days of treatment during which the individual shows little or no improvement. Higher dosing should be accompanied by careful observation of the patient for side effects. If patients fail to show improvement on doses above the usual therapeutic range, the dose should be reduced.",
"   </p>",
"   <p>",
"    As an example, a patient treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    can be started on 2 mg administered as a single daily dose or 1 mg twice a day. If this dose is well tolerated (ie, minimal sedation, hypotension, or akathisia) the dose can be increased to 3 mg on the second day and 4 mg on the third day. Since 4 mg is in the therapeutic range for most patients, the clinician may then choose to continue this dose for an additional two weeks before considering an increase. If the patient shows only minimal or no improvement the dose can be increased up to 8 mg daily with careful monitoring for clinical response and side effects. Doses of risperidone above 8 mg daily are associated with substantial risk of EPS.",
"   </p>",
"   <p>",
"    Because of dose-related toxicities, antipsychotics should be used at the lowest dose that is effective for an individual. The toxicities of antipsychotic drugs typically increase with higher doses while therapeutic effects can reach a maximum. At high doses, the adverse effects of an antipsychotic may surpass the marginal benefit of dosage increases. As a result, increasing the dose of antipsychotic for a patient who is already experiencing significant EPS is unlikely to result in additional symptom reduction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7468570\">",
"    <span class=\"h2\">",
"     Course of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient with schizophrenia is administered an antipsychotic medication, the initial response is often a side effect such as sedation, restlessness, or postural hypotension. It is important to explain this to patients, or they may conclude that the medication is ineffective or worsening their condition. Most patients who will improve on an antipsychotic show the most rapid improvement in the first two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/9\">",
"     9",
"    </a>",
"    ]. Although the rate of improvement may slow after two weeks, patients will often continue to improve during subsequent weeks and months.",
"   </p>",
"   <p>",
"    During the first weeks of treatment, patients may first experience a decrease in the severity of symptoms. As a result, the impact of symptoms on patient behavior may be reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/10\">",
"     10",
"    </a>",
"    ]. Hallucinations or delusions may be less frightening or the patient may find that they can distract themselves by focusing their attention elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/11\">",
"     11",
"    </a>",
"    ]. Delusions that are based on misinterpretations from an earlier time may linger, whereas the tendency to misinterpret new information may be reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956392854\">",
"    <span class=\"h2\">",
"     Medication changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two basic strategies for changing antipsychotics are [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A standard cross-titration for a stable patient: Simultaneous taper of the current medication with titration of the replacement drug in three to four steps over several days to several weeks.",
"     </li>",
"     <li>",
"      For patients at higher risk of relapse, the current medication is maintained at its full dose as the new medication is increased. Once the second drug has reached its target dose, the first medication may be gradually decreased and discontinued. In most cases this change can be managed in one to two weeks.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Discontinuation of antipsychotic medications is generally well tolerated, except for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , for which both cholinergic rebound and withdrawal-emergent movement disorders have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. A slow taper of clozapine over one to two weeks is recommended.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     Chlorpromazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    can also cause cholinergic rebound and should be reduced over a week or more. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16350492\">",
"    <span class=\"h2\">",
"     Management of refractory symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be observed on a stable dose of an antipsychotic for two to six weeks before concluding the drug is ineffective. The duration of the trial will vary depending on a number of factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although patients improve most rapidly during the first two weeks, they may continue to improve for several weeks or even months on a stable dose [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      However, recent evidence suggests that if patients show only a minimal response to an antipsychotic drug during the first two weeks, it is unlikely that the individual will have a robust response [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/17\">",
"       17",
"      </a>",
"      ]. The 2009 Schizophrenia PORT recommends that trials last for two to six weeks. This timeframe will be slightly longer for antipsychotics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/59/35767?source=see_link\">",
"       iloperidone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , which require slow titration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once it is concluded that the current antipsychotic is inadequate, based on lack of efficacy or side effects, there are a number of options for the next step of treatment, including increasing the dose of the current medication, changing to another antipsychotic, adding a second antipsychotic, and changing to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16350506\">",
"    <span class=\"h3\">",
"     Changing to another antipsychotic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Switching antipsychotics can be helpful when a poor response is related to side effects. As an example, in the large US effectiveness study of antipsychotic treatment for schizophrenia, the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE), patients who gained weight during the first phase of antipsychotic treatment frequently lost weight when they were changed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    , an antipsychotic that is not associated with weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Switching antipsychotics is less clearly beneficial when the initial medication lacked effectiveness. Most studies have shown that poor responders to one antipsychotic are likely to be poor responders to another antipsychotic except when the second agent is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H108920615\">",
"     'Clozapine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As an example, an analysis of patients who were on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    prior to the CATIE trial showed that the patients on olanzapine or risperidone who were randomly assigned to continue the same antipsychotic had better outcomes than patients who were randomly assigned to change antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H956392854\">",
"     'Medication changes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16350513\">",
"    <span class=\"h3\">",
"     Adding a second antipsychotic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians often add a second antipsychotic when patients have a suboptimal response to a single drug. Little empirical evidence supports this practice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/20\">",
"     20",
"    </a>",
"    ]. Although some randomized trials indicated that augmentation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    with another antipsychotic may have some benefit, a meta-analysis of this practice found the supporting evidence to be weak [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H108920615\">",
"    <span class=\"h3\">",
"     Clozapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    for patients who experience persistent and clinically significant positive symptoms of schizophrenia after trials of two other antipsychotic medications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/22\">",
"     22",
"    </a>",
"    ]. Clozapine can cause life-threatening agranulocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/23\">",
"     23",
"    </a>",
"    ] and other severe side effects. Guidelines for clozapine prescribing, dosing, monitoring, and side-effect management are described separately. A comparison of clozapine to other second-generation antipsychotic drugs is also described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=see_link\">",
"     \"Guidelines for prescribing clozapine in schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Randomized trials have shown that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    is more effective than other antipsychotics in treating patients with schizophrenia that has responded poorly to prior antipsychotic trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial compared treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      (up to 900 mg daily) to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      (up to 1800 mg daily) in 268 patients with schizophrenia who had failed to respond to at least three different first-generation antipsychotics [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/26\">",
"       26",
"      </a>",
"      ]. After a six week treatment period, a greater proportion of clozapine-treated patients experienced a clinically significant response compared to patients in the chlorpromazine-treated group (30 versus 4 percent). Patients were classified as having responded to a clinically significant extent using criteria developed a priori: if they experienced a reduction greater than 20 percent from baseline in the Brief Psychiatric Rating Scale total score plus either a posttreatment Clinical Global Impressions scale score of 3 (mild) or less, or a posttreatment BPRS total score of 35 or lower.",
"     </li>",
"     <li>",
"      In the Clinical Antipsychotic Trials for Interventions Effectiveness (CATIE) trial, 99 patients with schizophrenia who discontinued treatment with a second-generation antipsychotic were randomly assigned to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/25\">",
"       25",
"      </a>",
"      ]. Time to discontinuation for any reason was longer for clozapine (10.5 months) than for quetiapine (3.3 months), or risperidone (2.8 months). Time to discontinuation because of inadequate clinical effect was longer for clozapine than for any of the three other drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    has been shown in randomized trials to reduce suicide attempts in patients with schizophrenia and schizoaffective disorder at high risk for suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/27\">",
"     27",
"    </a>",
"    ]. A patient with schizophrenia who has persistent suicidal ideation warranting clinician concern may benefit from a trial of clozapine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=see_link\">",
"     \"Suicidal ideation and behavior in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2759148\">",
"    <span class=\"h3\">",
"     High-dose treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most careful studies of doses above the recommended range have not found higher doses to be more effective than the maximal recommended dose [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. If used, trials of higher doses should be time limited, with reassessment planned within three months. Unless clear evidence of improvement is seen, high doses should not be continued [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18522653\">",
"    <span class=\"h2\">",
"     Management of agitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical management of the acutely agitated patient with schizophrenia is a common objective on inpatient units and other settings. Agitation can be defined as a state characterized by motor restlessness, excitement, and mental tension. Treatment of agitation in patients with schizophrenia should be guided by the cause, which can include extrapyramidal symptoms (EPS), substance use, or psychosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13510982\">",
"    <span class=\"h3\">",
"     Extrapyramidal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Akathisia can be difficult to distinguish from psychotic agitation when patients are unable to describe the experience of restlessness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/31\">",
"     31",
"    </a>",
"    ]. Akathisia can be treated with a benzodiazepine; eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    can be started at 0.5 mg orally twice daily and incrementally increased to a maximum of 6 to 10",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13510886\">",
"    <span class=\"h3\">",
"     Substance use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up",
"    to half of individuals with schizophrenia have a comorbid substance use disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/32\">",
"     32",
"    </a>",
"    ]. Use of stimulants such as phencyclidine (PCP), methamphetamine, and cocaine can cause agitation as can withdrawal from alcohol or benzodiazepines. Agitation from substance use or withdrawal can be diagnosed by a history, physical exam, and toxicology. (See",
"    <a class=\"local\" href=\"#H613520365\">",
"     'Pharmacotherapy for comorbid disorders'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=see_link\">",
"     \"Dual diagnosis: Severe mental illness and substance use disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13510900\">",
"    <span class=\"h3\">",
"     Psychosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychotic symptoms of schizophrenia, such as frightening delusions, suspiciousness, and command hallucinations can cause patients to become agitated. The agitation associated with psychosis can be treated with an antipsychotic or an antipsychotic combined with a benzodiazepine. The selection of a drug and the route of administration depend on a number of considerations including the urgency of calming the patient and the cooperativeness of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/33\">",
"     33",
"    </a>",
"    ]. As noted below, the choice of an antipsychotic depends on the formulation selected. It is important to note that the treatment goal is to induce a calmer state, which can often be accomplished without inducing sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13511001\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although antipsychotic medications can take days to weeks before having a robust antipsychotic effect, they generally have a calming effect within minutes for agitated patients. The route of administration influences time to onset, as described below (",
"    <a class=\"graphic graphic_table graphicRef60846 \" href=\"UTD.htm?32/7/32893\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=see_link\">",
"     \"First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Standard oral formulations: Although many clinicians tend to favor sedating antipsychotics for agitated patients, non-sedating agents can also be effective for reducing agitation.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      1 to 2 mg or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      5 to 10 mg will usually be effective in these circumstances.",
"     </li>",
"     <li>",
"      Oral rapidly dissolving formulations: Oral rapidly dissolving formulations are available for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      . These formulations are helpful when a patient is willing to take a pill by mouth, but either cannot or does not swallow it. Dosing for these formulations is the same as for standard oral formulations, eg, risperidone 1 to 2 mg or olanzapine 5 to 10 mg.",
"     </li>",
"     <li>",
"      Short-acting intramuscular (IM) injectable formulations (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"       ziprasidone",
"      </a>",
"      ): Olanzapine 5 or 10 mg administered intramuscularly is a good choice under most circumstances. IM haloperidol is effective but should be given with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"       benztropine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      to reduce the risk of severe EPS including dystonias.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      5 mg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      2mg, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/55/3958?source=see_link\">",
"       benztropine",
"      </a>",
"      1mg given intramuscularly can be effective to treat severe agitation in schizophrenia. &nbsp;",
"     </li>",
"     <li>",
"      We advise against the use of IM",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      , which can induce severe postural hypotension. &nbsp;",
"     </li>",
"     <li>",
"      Akathisia from any IM antipsychotic can contribute to agitation.",
"     </li>",
"     <li>",
"      Injectable IM antipsychotics have two potential advantages over oral antipsychotics. First, they can be administered safely to uncooperative individuals. Second, patients reach an effective plasma concentration sooner than with oral formulations. For example, patients may experience a calming effect within 10 to 30 minutes following IM administration. Calming effects may take 30 to 60 minutes following oral administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although repeat administration of an oral or intramuscular antipsychotic is common when the prior dose does not sufficiently reduce agitation, the overall antipsychotic dose should be limited, because these medications can cause significant side effects such as hypotension, EPS, and sedation, particularly at high doses over a brief period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/9\">",
"     9",
"    </a>",
"    ]. Maximum antipsychotic doses are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef60846 \" href=\"UTD.htm?32/7/32893\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    To limit the amount of antipsychotic used, most physicians either start with a combination of an antipsychotic and benzodiazepine or use a benzodiazepine when patients fail to respond to one or two doses of an antipsychotic for agitation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    can be administered as 1 to 2 mg orally or 0.5 to 1 mg intramuscularly for calming.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16350527\">",
"    <span class=\"h2\">",
"     Managing first episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in a first psychotic episode tend to have higher response rates than patients who have experienced multiple psychotic episodes. These individuals also respond to lower antipsychotic doses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/34\">",
"     34",
"    </a>",
"    ]. At the same time, younger patients and first episode patients have a greater vulnerability to side effects such as weight gain and extrapyramidal side effects (EPS) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/35\">",
"     35",
"    </a>",
"    ]. Since many first episode patients are also reluctant to take an antipsychotic, it is important to minimize adverse effects.",
"   </p>",
"   <p>",
"    The Schizophrenia Patient Outcomes Research Team (PORT) recommended treating first episodes with antipsychotics other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    . Both of these medications are associated with more weight gain, insulin resistance and dyslipidemia than other antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, clozapine can cause agranulocytosis.",
"   </p>",
"   <p>",
"    The Schizophrenia PORT recommended that first-episode patients receive antipsychotic doses in the lower half of the recommended dose range [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/3\">",
"     3",
"    </a>",
"    ]. As examples, a first-episode patient would be treated with 1 to 3 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    or 10 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    daily. An exception to this recommendation should be made for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    , which may require titration to 500 to 600 mg daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16350534\">",
"    <span class=\"h1\">",
"     MAINTENANCE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have recovered from an acute psychotic episode will usually reach a stable or maintenance phase in which psychotic symptoms are reasonably well controlled. The goal of maintenance antipsychotic treatment of schizophrenia is to minimize symptoms and functional impairments, avoid relapses, and promote recovery that allows self-determination, full integration into society, and pursuit of personal goals.",
"   </p>",
"   <p>",
"    Antipsychotic medication should be continued after patients recover from an acute episode, at the same dose that was effective in the acute phase [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/3\">",
"     3",
"    </a>",
"    ]. Findings from randomized trials support the effectiveness of antipsychotics for preventing relapse in patients with schizophrenia who respond to acute antipsychotic treatment. A meta-analysis of 6493 patients with schizophrenia in 65 randomized trials compared continuation of antipsychotic medication to withdrawal of the medication and replacement with placebo during maintenance treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients who continued to take an antipsychotic experienced lower relapse rates at one year compared to the placebo group (27 versus 64 percent; number needed to treat to benefit = 3, 95% CI 2&ndash;3).",
"   </p>",
"   <p>",
"    There is insufficient evidence to inform decision making on the duration of maintenance therapy for schizophrenia. Based on our clinical experience, we suggest that antipsychotic treatment should be continued indefinitely, even for patients who have achieved remission from a first psychotic episode. Patients and their clinician should make a joint decision about the duration of treatment. &nbsp;",
"   </p>",
"   <p>",
"    The considerations regarding selection of antipsychotic medication for maintenance treatment mirror those for pharmacotherapy during the acute phase. (See",
"    <a class=\"local\" href=\"#H2758642\">",
"     'Antipsychotic drug efficacy and selection'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16350541\">",
"    <span class=\"h2\">",
"     Medication adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-acting injectable antipsychotics may be useful for patients with schizophrenia who experience frequent relapses due to non-adherence to antipsychotic medications. They also may be helpful for patients who will not take oral antipsychotics regularly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other strategies to promote better adherence to antipsychotics include simplifying medication regimens (eg fewer medications, fewer pills, fewer daily doses) and active engagement of patients in treatment planning (ie, shared decision making).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H613520157\">",
"    <span class=\"h2\">",
"     Treatment of cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improving cognitive impairment has increasingly become an objective of treatment for schizophrenia. Preliminary studies suggest that antipsychotic medication may improve cognition when received early in the course of schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Studies of patients with chronic schizophrenia have generally found less improvement in cognition during antipsychotic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Trials of other medications (including n-methyl-d-aspartate (NMDA) glutamatergic receptor agonists, glycine, D-serine, ampakine CX516, D-cycloserine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/27/6582?source=see_link\">",
"     galantamine",
"    </a>",
"    ) have failed to show significant benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/42-50\">",
"     42-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H613520365\">",
"    <span class=\"h2\">",
"     Pharmacotherapy for comorbid disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depressive disorders and anxiety disorders can be challenging to diagnose in patients with schizophrenia. A primary comorbid disorder needs to be distinguished from symptoms of schizophrenia, antipsychotic drug side effects, and other clinical presentations. Properly diagnosed, however, these syndromes can respond to antidepressant and anxiolytic medications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25944?source=see_link\">",
"     \"Depression in schizophrenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2105?source=see_link\">",
"     \"Anxiety in schizophrenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Substance abuse and dependence occur at a high prevalence in schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/52\">",
"     52",
"    </a>",
"    ]. The combination of a severe mental illness and a substance use disorder (SUD), commonly described as &ldquo;dual diagnosis&rdquo;, is associated with increased morbidity, poorer functioning, decreased adherence to medication, and higher rates of relapse compared to either disorder individually [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29241/abstract/53\">",
"     53",
"    </a>",
"    ]. Integrated treatment strategies for dual diagnosis that include pharmacotherapy have been developed for individuals with schizophrenia and SUDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=see_link\">",
"     \"Dual diagnosis: Severe mental illness and substance use disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/37/44625?source=see_link\">",
"       \"Patient information: Schizophrenia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956391910\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients treated with an antipsychotic for schizophrenia should be assessed prior to treatment if possible and at regular intervals for: (See",
"      <a class=\"local\" href=\"#H956391942\">",
"       'Pre-treatment assessment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Signs of a movement disorder including extrapyramidal symptoms and tardive dyskinesia",
"     </li>",
"     <li>",
"      Symptoms of metabolic syndrome including measurements of body mass index, waist circumference, hemoglobin A1c, serum lipids, blood pressure",
"     </li>",
"     <li>",
"      ECG for patients with a history of cardiac disease or when starting an antipsychotic that prolongs the QT interval",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend antipsychotic medication as first-line medication treatment for acute and maintenance phase treatment for schizophrenia (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2758642\">",
"       'Antipsychotic drug efficacy and selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The selection of which antipsychotic medication to use for an individual patient with schizophrenia should be made based on patient clinical factors and the side effect profiles of antipsychotic drugs. With the exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      for patients with refractory symptoms, there is not convincing evidence to favor one antipsychotic over the others based on efficacy. (See",
"      <a class=\"local\" href=\"#H2758642\">",
"       'Antipsychotic drug efficacy and selection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Because",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      is associated with significant weight gain and metabolic adverse effects, leading guidelines state that it should not be used as a first-line agent for first-episode patients, but should be considered for patients who fail treatment with a first-line agent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      for patients who experience persistent and clinically significant positive symptoms of schizophrenia after trials of two other antipsychotic medications (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Clozapine can cause life-threatening agranulocytosis and other severe side effects. Guidelines for clozapine prescribing, monitoring, and side-effect management are described separately. (See",
"      <a class=\"local\" href=\"#H108920615\">",
"       'Clozapine'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=see_link\">",
"       \"Guidelines for prescribing clozapine in schizophrenia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"       \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other strategies for the patient with schizophrenia who has not adequately responded to an antipsychotic drug include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Changing to another antipsychotic has been shown to be an effective strategy for addressing side effect problems but is not clearly associated with improved efficacy, with the exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H16350506\">",
"       'Changing to another antipsychotic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adding a second antipsychotic medication has not been proven efficacious in randomized trials. For patients with psychotic symptoms that do not respond to two trials of antipsychotic monotherapy, a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      is strongly recommended before combining two antipsychotics. (See",
"      <a class=\"local\" href=\"#H16350513\">",
"       'Adding a second antipsychotic'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hospitalized patients with schizophrenia may require treatment for agitation. If agitation is associated with psychotic symptoms of schizophrenia, it can be treated with a standard oral formulation, rapid dissolving, or intramuscularly injected antipsychotic, depending on the level of patient participation. Other causes of agitation should be ruled out, including akathisia and substance abuse or withdrawal. (See",
"      <a class=\"local\" href=\"#H18522653\">",
"       'Management of agitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Long-acting injectable (LAI) antipsychotic medication may be useful for patients with schizophrenia when non-adherence to oral antipsychotics leads to frequent relapse. LAI antipsychotics are administered at two to four week intervals. As an example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"       fluphenazine",
"      </a>",
"      decanoate can be administered at a dose between 6.25 to 50 mg intramuscularly every two weeks. Extrapyramidal symptoms can be prominent at higher doses. (See",
"      <a class=\"local\" href=\"#H16350541\">",
"       'Medication adherence'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=see_link\">",
"       \"Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     Murray CJL, Lopez AD. The Global Burden of Disease, Harvard University Press, Cambridge, MA 1996. p.21.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/3\">",
"      Buchanan RW, Kreyenbuhl J, Kelly DL, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/4\">",
"      Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995; 21:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/5\">",
"      Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/6\">",
"      McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/7\">",
"      Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/8\">",
"      Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull 2009; 35:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/9\">",
"      Agid O, Kapur S, Arenovich T, Zipursky RB. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 2003; 60:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/10\">",
"      Mizrahi R, Kiang M, Mamo DC, et al. The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. Schizophr Res 2006; 88:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/11\">",
"      Mizrahi R, Bagby RM, Zipursky RB, Kapur S. How antipsychotics work: the patients' perspective. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:859.",
"     </a>",
"    </li>",
"    <li>",
"     Jibson MD, Tandon R. Treatment of acute psychotic episodes. In: Schizophrenia: a new guide for clinicians, Csernansky, JG.  (Eds), Marcel Dekker, New York 2001. p.107.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/13\">",
"      Kinon BJ, Basson BR, Gilmore JA, et al. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 2000; 61:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/14\">",
"      Stanilla JK, de Leon J, Simpson GM. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. J Clin Psychiatry 1997; 58:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/15\">",
"      Ahmed S, Chengappa KN, Naidu VR, et al. Clozapine withdrawal-emergent dystonias and dyskinesias: a case series. J Clin Psychiatry 1998; 59:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/16\">",
"      Shiovitz TM, Welke TL, Tigel PD, et al. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996; 22:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/17\">",
"      Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010; 35:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/18\">",
"      Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006; 163:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/19\">",
"      Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006; 163:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/20\">",
"      G&ouml;ren JL, Parks JJ, Ghinassi FA, et al. When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 2008; 34:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/21\">",
"      Barbui C, Signoretti A, Mul&egrave; S, et al. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009; 35:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/22\">",
"      Kreyenbuhl J, Buchanan RW, Dickerson FB, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull 2010; 36:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/23\">",
"      Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/24\">",
"      Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/25\">",
"      McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/26\">",
"      Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/27\">",
"      Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/28\">",
"      Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008; 28:392.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Psychiatrists. Consensus statement on high dose antipsychotic medication. CR138, Royal College of Psychiatrists, London 2006.",
"    </li>",
"    <li>",
"     UK National Institute for Health and Clinical Excellence Guidelines file://guidance.nice.org.uk/CG/WaveR/26.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/31\">",
"      Buckley PF. Treating movement disorders and akathisia as side effects of antipsychotic pharmacotherapy. J Clin Psychiatry 2008; 69:e14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/32\">",
"      Dixon L. Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophr Res 1999; 35 Suppl:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/33\">",
"      Marder SR. Treatment of agitation in patients with schizophrenia. J Clin Psychiatry 2008; 69:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/34\">",
"      Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 1985; 46:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/35\">",
"      Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/36\">",
"      van Os J, Howes OD. Antipsychotic drugs for prevention of relapse. Lancet 2012; 379:2030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/37\">",
"      Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009; 166:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/38\">",
"      Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry 2007; 164:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/39\">",
"      Harvey PD, Patterson TL, Potter LS, et al. Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning. Am J Psychiatry 2006; 163:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/40\">",
"      Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007; 64:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/41\">",
"      Sergi MJ, Green MF, Widmark C, et al. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry 2007; 164:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/42\">",
"      Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007; 164:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/43\">",
"      Tuominen HJ, Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev 2006; :CD003730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/44\">",
"      Goff DC, Herz L, Posever T, et al. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl) 2005; 179:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/45\">",
"      Kohler CG, Martin EA, Kujawski E, et al. No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cogn Neuropsychiatry 2007; 12:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/46\">",
"      Mazeh D, Zemishlani H, Barak Y, et al. Donepezil for negative signs in elderly patients with schizophrenia: an add-on, double-blind, crossover, placebo-controlled study. Int Psychogeriatr 2006; 18:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/47\">",
"      Freudenreich O, Herz L, Deckersbach T, et al. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2005; 181:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/48\">",
"      Sharma T, Reed C, Aasen I, Kumari V. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Schizophr Res 2006; 85:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/49\">",
"      Kumari V, Aasen I, ffytche D, et al. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study. Neuroimage 2006; 29:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/50\">",
"      Buchanan RW, Conley RR, Dickinson D, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008; 165:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/51\">",
"      Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009; 35:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29241/abstract/52\">",
"      Kessler RC, Nelson CB, McGonagle KA, et al. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996; 66:17.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm Series, National Academy Press, 2006. p.210.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14805 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-1.234.2.38-DECD7EA589-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29241=[""].join("\n");
var outline_f28_35_29241=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H956391910\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16350450\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16350597\">",
"      ACUTE PHASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H956391942\">",
"      Pre-treatment assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2758642\">",
"      Antipsychotic drug efficacy and selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13510771\">",
"      - Antipsychotic drug categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16350464\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7468570\">",
"      Course of response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H956392854\">",
"      Medication changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16350492\">",
"      Management of refractory symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16350506\">",
"      - Changing to another antipsychotic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16350513\">",
"      - Adding a second antipsychotic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H108920615\">",
"      - Clozapine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2759148\">",
"      - High-dose treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18522653\">",
"      Management of agitation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13510982\">",
"      - Extrapyramidal symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13510886\">",
"      - Substance use",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13510900\">",
"      - Psychosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13511001\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16350527\">",
"      Managing first episodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16350534\">",
"      MAINTENANCE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16350541\">",
"      Medication adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H613520157\">",
"      Treatment of cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H613520365\">",
"      Pharmacotherapy for comorbid disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H956391910\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14805\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14805|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/57/33694\" title=\"table 1\">",
"      Adverse effects for antipsychotic meds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/58/31663\" title=\"table 2\">",
"      Dosage and pharmacology of antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/7/32893\" title=\"table 3\">",
"      Antipsychotics for management of acute agitation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/3/2105?source=related_link\">",
"      Anxiety in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/21/25944?source=related_link\">",
"      Depression in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=related_link\">",
"      Dual diagnosis: Severe mental illness and substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7562?source=related_link\">",
"      First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6793?source=related_link\">",
"      Guidelines for prescribing clozapine in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/37/44625?source=related_link\">",
"      Patient information: Schizophrenia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/9/30871?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Long-acting injectable antipsychotic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/44/8904?source=related_link\">",
"      Psychosocial interventions for schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20057?source=related_link\">",
"      Schizophrenia: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10377?source=related_link\">",
"      Suicidal ideation and behavior in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_35_29242="The spinocerebellar ataxias";
var content_f28_35_29242=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The spinocerebellar ataxias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/35/29242/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/35/29242/contributors\">",
"     Puneet Opal, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/35/29242/contributors\">",
"     Huda Y Zoghbi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/35/29242/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/35/29242/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/35/29242/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/35/29242/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/35/29242/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/35/29242/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous classification systems have been proposed for the autosomal dominant ataxias, which are distinct from the autosomal recessive disorder, Friedreich ataxia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15432?source=see_link\">",
"     \"Friedreich ataxia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One system proposed by Anita Harding divided these disorders into autosomal dominant cerebellar ataxia types I, II, and III [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type I syndromes are ataxias with ophthalmoplegia, optic atrophy, dementia and extrapyramidal features",
"     </li>",
"     <li>",
"      Type II ataxias are associated with pigmented maculopathy with or without ophthalmoplegia or extrapyramidal features",
"     </li>",
"     <li>",
"      Type III syndromes are pure ataxic syndromes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the past, attempts were made to link the Harding classification system with the genetic forms of the spinocerebellar ataxias (SCA), but this is becoming unnecessary. We now favor a purely genetic classification based upon the genetic loci of the SCA. These loci have been numbered according to their order of identification: SCA1 through SCA36 (and the number continues to grow). Except for its historical interest, we tend to avoid the Harding classification since it is not particularly helpful in terms of narrowing the diagnosis.",
"   </p>",
"   <p>",
"    In addition to the SCAs, there are a few other genetic disorders that are inherited in a dominant manner and often present as ataxia. These are discussed in this review to complete the differential diagnosis of these chronic, progressive ataxic syndromes. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Disorders that resemble SCA'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A number of other hereditary ataxias have been identified and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=see_link\">",
"     \"Overview of the hereditary ataxias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF SCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 30 types of spinocerebellar ataxias (SCA) have been identified. Cerebellar ataxia is a feature of each type; other distinguishing features may suggest a particular type (",
"    <a class=\"graphic graphic_table graphicRef74269 \" href=\"UTD.htm?10/59/11198\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, only 60 to 75 percent of patients with SCA have mutations in the known loci [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/2\">",
"     2",
"    </a>",
"    ]. Furthermore, among patients with apparently idiopathic sporadic cerebellar ataxia (ie, no family history), an SCA mutation (types 1, 2, 3, 6, 7, 8, or 12), most often SCA6, or Friedreich ataxia, can be identified in approximately 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/3\">",
"     3",
"    </a>",
"    ]. Online resources such as the",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim/\">",
"     Online Mendelian Inheritance of Man",
"    </a>",
"    database can be used to keep up with advances in this area.",
"   </p>",
"   <p>",
"    Several types of spinocerebellar ataxias (SCA1, 2, 3, 6, 7, and 17) are associated with expansion of CAG repeats in the region that encodes for polyglutamine tracts in the protein products, similar to that seen in Huntington disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8599?source=see_link\">",
"     \"Huntington disease: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Wild-type chromosomes with a stable CAG repeat have 6 to 34 repeat units; more than 36 repeats results in an unstable, expanded, disease-causing allele [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/4\">",
"     4",
"    </a>",
"    ]. Expansion of CAG repeats is thought to produce a toxic \"gain of function\" (ie, disease develops because the mutant form of the protein gains a new function, not because the protein loses its normal function). The disorders associated with expansion of CAG repeats share several clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They typically present in middle age, with progressive ataxia, neuronal dysfunction and eventual neuronal loss during the ensuing 10 to 20 years.",
"     </li>",
"     <li>",
"      The greater the number of CAG repeats on expanded alleles, the earlier the age of onset and more severe the disease. Thus, juvenile onset disease typically is associated with very large expansions.",
"     </li>",
"     <li>",
"      As examples of the variability in onset, a prospective study reported the mean age of onset for several common types of SCAs as follows [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/5\">",
"       5",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      SCA1, 37 years (range 5 to 65)",
"     </li>",
"     <li>",
"      SCA2, 35 years (range 7 to 66)",
"     </li>",
"     <li>",
"      SCA3, 37 years (range 5 to 66)",
"     </li>",
"     <li>",
"      SCA6, 55 years (range 31 to 77)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The repeats show both somatic and germline instability. As a result, successive generations of affected families experience anticipation, a phenomenon characterized by earlier onset and a progressively worse phenotype in subsequent generations.",
"     </li>",
"     <li>",
"      Only a certain subset of neurons is vulnerable to dysfunction, even though the relevant protein is expressed widely throughout the brain and other tissues.",
"     </li>",
"     <li>",
"      Cerebellar atrophy is the most common reported finding. Brainstem atrophy is variable, being more characteristic of SCA types 1, 2, and 7. Neurodegeneration of the reticulotegmental nucleus of the pons has been reported for patients with SCA types 1, 2, and 3; this nucleus plays a role in the performance of horizontal smooth pursuit eye movements and in the accuracy of horizontal saccades [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H605308128\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the age of onset and rate of disability progression for the more common SCAs vary according to individual differences in the length of the causative CAG trinucleotide repeat. Most of the available data concern the most four most common types of SCAs, which are SCA1, SCA2, SCA3, and SCA6. The following observations have been made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients require a wheelchair by 10 to 15 years after symptom onset.",
"     </li>",
"     <li>",
"      An earlier report of disease progression and survival for SCA1, SCA2 and SCA3 found that SCA1 had a more rapid progression and shortest life expectancy, with death occurring at a median age of 56 years [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A later prospective study also found that progression was fastest in SCA1, followed by SCA2 and SCA3, in which progression was similar; progression was slowest for SCA6 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disability and mortality data for the other types of SCAs are limited. However, in most there is disability progression over one to two decades on average, and lifespan is shortened, though some are compatible with a normal lifespan [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effective treatment is available for the SCAs, but small studies have investigated a variety of agents to treat ataxia. As examples, one report described transient improvement in cerebellar symptoms with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    10 mg in four out of five family members with SCA type 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/9\">",
"     9",
"    </a>",
"    ], and an eight-week placebo-controlled trial of 20 patients with SCA3 found that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    led to improvement in some, but not all, measures of cerebellar dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/10\">",
"     10",
"    </a>",
"    ]. These findings require confirmation in larger studies.",
"   </p>",
"   <p>",
"    Animal studies suggest that polyglutamine neurotoxicity can be suppressed by overexpression of heat shock proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. The technique of gene silencing with RNA interference has also shown promise in a mouse model of SCA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/14\">",
"     14",
"    </a>",
"    ]. The potential applicability of these findings to human disease remains speculative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF SCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Overview of SCA'",
"    </a>",
"    above), over 30 types of spinocerebellar ataxias (SCA) have been identified. Cerebellar ataxia is a feature of each type; other distinguishing features may suggest a particular type (",
"    <a class=\"graphic graphic_table graphicRef74269 \" href=\"UTD.htm?10/59/11198\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     SCA1",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCA1 is caused by a CAG repeat expansion on chromosome 6p23 in the coding region of the SCA1, the product of which is called ataxin 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/15\">",
"     15",
"    </a>",
"    ]. The normal function of ataxin 1 is not known. Mutant ataxin 1 aggregates into single nuclear inclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/16\">",
"     16",
"    </a>",
"    ]. This aggregation reflects, at least in part, resistance of the mutant protein to degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition to mutant ataxin 1, these inclusions also stain positive for chaperones and components of the ubiquitin-proteasomal pathway, both of which are important for protein clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/11\">",
"     11",
"    </a>",
"    ]. Ubiquitination and proteasomal degradation appear to represent appropriate responses because interventions to prevent these processes in SCA1 and other polyglutamine diseases increase neuronal toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenetic role of the nuclear inclusions themselves is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. Mutant ataxin 1 has been found to alter neuronal gene expression, which may be more important in pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/21\">",
"     21",
"    </a>",
"    ]. Another feature that is not well understood is the tissue-specific and brain region-specific instability of the expanded allele [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/22\">",
"     22",
"    </a>",
"    ]. Ataxin 1 interacts with the cerebellar leucine-rich acidic nuclear protein (LANP); this protein is expressed primarily in Purkinje cells, the major site of involvement in SCA1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/23\">",
"     23",
"    </a>",
"    ]. The interaction is stronger when the number of CAG repeats is increased.",
"   </p>",
"   <p>",
"    Ataxin 1 is phosphorylated on serine 776 by Akt kinase and this serine is critical for mediating the pathogenesis of SCA1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Several isoforms of the regulatory protein 14-3-3 interact with ataxin 1 in an S776-dependent manner. These interactions are enhanced by an expanded glutamine tract in ataxin 1. In cultured cells and in an SCA1 Drosophila model, the 14-3-3 protein impedes the clearance of ataxin 1 and enhances neurodegeneration; in contrast, haploinsufficiency of Akt suppresses neurodegeneration. These studies identified",
"    <span class=\"nowrap\">",
"     PI3kinase/Akt",
"    </span>",
"    as a possible therapeutic target in SCA1.",
"   </p>",
"   <p>",
"    SCA1 typically presents in the third to fourth decade of life, but tremendous variability in onset and clinical severity exists. It is characterized clinically by progressive cerebellar ataxia, dysarthria, and bulbar dysfunction. Other findings include hyperreflexia, increased tone, extensor plantar responses, and, in some patients, masking of these upper motor neuron findings by peripheral nervous system disease that results in wasting of the extremities and generalized fasciculations.",
"   </p>",
"   <p>",
"    In different populations, SCA1 accounts for 3 to 16 percent of autosomal dominant cerebellar ataxias [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. Expanded SCA1 genes contain from 36 to 81 uninterrupted CAG repeats (normal alleles have 6 to 44 repeats; when the tract contains more than 21 CAGs, it is interrupted by a few CAT units).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     SCA2",
"    </span>",
"    &nbsp;&mdash;&nbsp;In different populations, SCA2 accounts for 6 to 18 percent of SCA kindreds [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/26,28-31\">",
"     26,28-31",
"    </a>",
"    ]. SCA2 is distinguished clinically from SCA1 by the presence of slow saccadic eye movements [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/32\">",
"     32",
"    </a>",
"    ]. It results from expanded polyglutamine tracts in the ataxin 2 gene (ATXN2) on chromosome 12q24, which encodes a protein called ataxin 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Ataxin 2 contains structural elements that appear to be important in RNA splicing. In contrast to the nuclear inclusions in SCA1, mutant ataxin 2 is associated with cytoplasmic microaggregates [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disease-causing alleles usually contain 35 to 64 CAG repeats (normal 14 to 31 repeats). An inverse relationship exists between disease onset and severity and the number of CAG repeats [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/36\">",
"     36",
"    </a>",
"    ]. When ATXN2 alleles contain more than 200 repeats, the disease can present as early as infancy with hypotonia, developmental delay, infantile spasms, autonomic dysfunction, dysphagia, and retinitis pigmentosa [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. On the other hand, disease onset in late adulthood, manifested as ataxia, slow saccades, and hyporeflexia, has been described in two patients with 33 CAG repeats [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/39\">",
"     39",
"    </a>",
"    ]. An inverse relationship also exists between saccadic eye movement velocity and the number of CAG repeats [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one ethnic Chinese family, SCA2 has been associated with a predominant phenotype resembling dopa-responsive Parkinson disease or an ataxia-parkinsonism phenotype similar to progressive supranuclear palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=see_link\">",
"     \"Diagnosis of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, occasional patients with polyglutamine expansions in ATXN2 have a phenotype of motor neuron disease similar to or indistinguishable from amyotrophic lateral sclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and pathogenesis of amyotrophic lateral sclerosis\", section on 'Genetic susceptibility in sporadic ALS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Genetic background influences the phenotype in geographically distinct families. For example, mental deterioration has been described in an Italian family [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/37,42\">",
"     37,42",
"    </a>",
"    ], and chorea and dystonia have been described in families from Tunis and Martinique [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     SCA3 (Machado-Joseph disease)",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCA3, also known as Machado-Joseph disease (MJD), is the most common of the autosomal dominant SCAs. It is present in 21 to 23 percent of kindreds in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/27-29\">",
"     27-29",
"    </a>",
"    ], 12 percent in Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/30\">",
"     30",
"    </a>",
"    ], and as many as 48 percent in China [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     SCA3/MJD",
"    </span>",
"    gene is on the long arm of chromosome 14 (14q32) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]; it encodes a protein called ataxin 3 or MJD1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/45\">",
"     45",
"    </a>",
"    ]. The mutant gene has an increased number of CAG repeats (40 to more than 200 versus 12 to 41 (interrupted) in the wild-type allele). The wild-type protein predominantly is cytoplasmic, whereas mutant ataxin 3 is localized within the nucleus of neuronal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/47\">",
"     47",
"    </a>",
"    ]. The mutant protein forms nuclear inclusions and is associated with cell degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     SCA3/MJD",
"    </span>",
"    can be associated with a variety of symptoms other than ataxia. They include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Slow saccades and saccadic pursuit",
"     </li>",
"     <li>",
"      Lid retraction that gives the impression of a persistent stare",
"     </li>",
"     <li>",
"      Signs of brainstem dysfunction such as dysarthria, difficulty in swallowing, poor cough and tongue fasciculations",
"     </li>",
"     <li>",
"      Signs of upper and lower motor neuropathy; thus, tone can range from hypotonia to rigidity, reflexes can range from absent to exaggerated, and the plantar response is usually extensor",
"     </li>",
"     <li>",
"      Extrapyramidal features including rigidity and dystonia",
"     </li>",
"     <li>",
"      Muscle cramps and fasciculations [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cognitive impairments, such as verbal and visual memory deficits, impairment of verbal fluency, and visuospatial and constructional dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autonomic dysfunction with symptoms such as cold intolerance, nocturia, and orthostatic dizziness [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the past, MJD was subclassified into three types based upon the pattern of clinical features. Unfortunately, too many patients fell into more than one type for this classification to be clinically useful. Phenotypic variation is most likely a reflection of the number of CAG repeats and other genetic factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     SCA4",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCA4 has few features that distinguish it from the other hereditary ataxias, except perhaps for an exaggerated sensory axonal neuropathy and extensor plantar reflexes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/53\">",
"     53",
"    </a>",
"    ]. The gene locus maps to chromosome 16q22 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     SCA5",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCA5 is characterized by an almost pure cerebellar syndrome. It is a relatively mild disorder that typically begins between the ages of 20 and 30 and progresses slowly [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/55\">",
"     55",
"    </a>",
"    ]. Magnetic resonance imaging (MRI) reveals global cerebellar atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/55\">",
"     55",
"    </a>",
"    ]. The gene locus is in the centromeric region of chromosome 11 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/56\">",
"     56",
"    </a>",
"    ], and the disease has been associated with mutations in the beta III spectrin gene (SPTBN2 gene) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/57\">",
"     57",
"    </a>",
"    ]. The original kindred was descended from the paternal grandparents of Abraham Lincoln.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     SCA6",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCA6 shares many clinical features with type 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. It is associated with slowly progressive cerebellar ataxia that begins between the ages of 20 and 60; global cerebellar atrophy is seen on MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Other clinical features that may be seen include horizontal and vertical nystagmus and an abnormal vestibuloocular reflex [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SCA6 accounted for 15 to 17 percent of dominant cerebellar ataxias in two series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A population based molecular genetics study found that the point prevalence of SCA6 in northeast region of England was 1.59 in 100,000, and the number of individuals who had or were at risk of developing SCA was at least 1 in 19,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SCA6 is a polyglutamine disorder, but the CAG tract expansion is relatively small (21 to 33 repeats versus less than 18 in normal subjects). In one series of Japanese patients with SCA6, 9 of 35 had no apparent family history of ataxia; these patients had smaller CAG repeats (21 or 22) and later age of onset (65 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/60\">",
"     60",
"    </a>",
"    ]. A similar finding was noted in another report of patients with apparently idiopathic sporadic cerebellar ataxia. A mutation could be identified in 19 percent; SCA6 was the disorder most commonly identified in patients with late onset disease (47 to 68 years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/3\">",
"     3",
"    </a>",
"    ]. One patient who was homozygous for the SCA6 mutation had an earlier age of onset and more severe disease than did her heterozygous sister [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The product of the SCA6 gene on 19p13 is the alpha-1A subunit of the",
"    <span class=\"nowrap\">",
"     P/Q",
"    </span>",
"    type calcium channel [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/62\">",
"     62",
"    </a>",
"    ]. Possible mechanisms of neuronal cell degeneration include increased calcium entry and cytoplasmic aggregates of channel protein [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The same gene has been implicated in two other disorders: episodic ataxia type 2 and familial hemiplegic migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Although the mutations are different, some overlap of symptoms exists among these disorders. SCA6 can present with intermittent ataxia in the early stages, similar to episodic ataxia, and all three conditions often are associated with cerebellar atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     SCA7",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCA7 accounts for approximately 2 to 5 percent of dominant spinocerebellar ataxias [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. It has a variable clinical expression, depending in part upon the age at onset [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the onset is in childhood, seizures, myoclonus, and cardiac involvement accompany the ataxia, and visual loss develops early in the disease course. Extremely long (&gt;150) CAG repeats are associated with onset in infancy and evidence of systemic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/68\">",
"       68",
"      </a>",
"      ]. A severe infantile phenotype associated with over 200 CAG repeats has also been described [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In adult-onset cases, smaller repeat expansions tend to manifest first as ataxia, whereas larger repeats can cause pigmentary macular degeneration leading to visual loss before ataxia develops [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This visual loss had been thought to be unique to SCA7 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/70\">",
"     70",
"    </a>",
"    ], but retinal degeneration has been documented in childhood-onset cases of SCA2 and SCA1 caused by very large repeats. Nevertheless, in adults, defects in color vision and electroretinogram abnormalities might suggest the diagnosis early in the disease course [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SCA7 is a glutamine repeat disorder that maps to chromosome 3p12 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. The number of CAG repeats varies between 37 and 306 (normal 4 to 35). Marked intergenerational instability is present, with expansion particularly likely upon paternal transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The product of the SCA7 gene is called ataxin 7 and is preferentially expressed in neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/72\">",
"     72",
"    </a>",
"    ]. Mice overexpressing mutant ataxin 7, but not wild-type ataxin 7, have features similar to those of the human disease, with neurodegeneration involving the cerebellum and retina [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     SCA8",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCA8 is difficult to distinguish clinically from the other SCAs. Affected patients typically have a slowly progressive, predominantly cerebellar ataxia affecting gait, swallowing, speech, and limb and eye movements, with variable age at onset [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Marked cerebral atrophy is found on MRI or CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/75\">",
"     75",
"    </a>",
"    ]. Neurodegeneration of Purkinje, inferior olivary, and nigral cells, accompanied by periaqueductal gliosis, was described in one Japanese family [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SCA8 is unusual because the pathogenesis involves a CTG expansion in the non-coding region of the ATXN8OS gene on chromosome 13q21 (70 to 250 repeats compared to 15 to 50 in normals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/77\">",
"     77",
"    </a>",
"    ]) and a complementary CAG repeat in the ATXN8 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Oddly, it is this particular range of repeats that is pathogenic, as opposed to any expansion; some unaffected individuals bear hundreds of repeats. The expansion is transcribed in both the forward and reverse directions to yield RNA with a noncoding CUG expansion from the ATXN8OS gene and a CAG transcript from the ATXN8 gene that encodes a string of polyglutamines [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/80\">",
"     80",
"    </a>",
"    ]. It is likely that both these products act in dominant toxic pathways. Genetic analysis of 37 families with SCA8 ataxia found that SCA8 expansions arose independently on three different haplotypes, supporting the direct role of CTG expansion in disease pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The CTG expansion found in SCA8 shows dramatic genetic instability and age dependent reduced disease penetrance. As an example, only one or two individuals in a given family may be affected by the disease, despite dominant inheritance. A maternal penetrance bias may exist, as CTG repeats tend to expand in mothers and contract in fathers (ie, fewer repeats in sperm than blood) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/74,79\">",
"     74,79",
"    </a>",
"    ]. The reduced penetrance in fathers may make the disease appear recessive or sporadic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     SCA types 9 to 20",
"    </span>",
"    &nbsp;&mdash;&nbsp;The remaining types of SCA are rare and less well characterized. Types 21 to 30 are described below. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'SCA types 21 to 36'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SCA9 has not been assigned to a clinical disorder.",
"     </li>",
"     <li>",
"      SCA10 exhibits phenotypic variability and is characterized by seizures and pure cerebellar ataxia in Mexican families [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/82\">",
"       82",
"      </a>",
"      ], cerebellar ataxia without epilepsy in Brazilian families [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/83\">",
"       83",
"      </a>",
"      ], and extrapyramidal signs, seizures, and ataxia in an Argentinean family [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/84\">",
"       84",
"      </a>",
"      ]. All reported families share American Indian ancestry. SCA10 exhibits anticipation, and the locus maps to chromosome 22q13 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/85,86\">",
"       85,86",
"      </a>",
"      ]. The disease is caused by expansion of ATTCT pentanucleotide repeats in the ataxin 10 gene initially identified in five Mexican families; normal alleles bear 10 to 22 repeats, while disease-causing alleles contain 800 to 4500 repeats [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCA11 is a relatively mild, pure cerebellar ataxia caused by mutations in the TTBK2 gene with a locus at 15q14-q21.3 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]. The TTBK2 gene encodes tau tubulin kinase-2, and neuropathologic examination of one affected individual revealed tau deposition and cerebellar degeneration [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/89\">",
"       89",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCA12 is a trinucleotide repeat disorder caused by a CAG trinucleotide expansion in the 5' UTR of a gene encoding a brain-specific regulatory subunit of protein phosphatase 2A [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/90\">",
"       90",
"      </a>",
"      ]. The normal range of repeats is 7 to 28; disease alleles bear 66 to 78 repeats. This ataxia often is complicated by tremors and dementia in the later stages. The genetic locus is 5q31-q33.",
"     </li>",
"     <li>",
"      SCA13 is characterized by cerebellar ataxia and mental retardation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/91\">",
"       91",
"      </a>",
"      ]. The gene locus is on chromosome 19q13, and heterozygous mutations of the potassium channel KCNC3 gene are associated with the disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCA14 is not a trinucleotide repeat disorder, but rather is caused by mutations in the protein kinase C gamma (PRKCG) gene, located on chromosome 19q13 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/93-97\">",
"       93-97",
"      </a>",
"      ]. SCA14 is characterized by slow progression and long duration. The disorder can have either a late onset (&ge;39 years) as pure cerebellar ataxia or an earlier onset with intermittent myoclonus followed by ataxia.",
"     </li>",
"     <li>",
"      SCA15 is a very slowly progressive pure cerebellar ataxia, with onset occurring from mid childhood to middle age [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/98-101\">",
"       98-101",
"      </a>",
"      ]. Additional clinical features may include a mild postural or action tremor and titubation. Neuroimaging typically reveals atrophy of the cerebellum, especially the vermis, but the cerebral hemispheres and brainstem are unaffected. Although initial analysis seemingly excluded the ITPR1 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/100\">",
"       100",
"      </a>",
"      ], later studies confirmed that SCA15 is caused by deletions or missense mutations in the ITPR1 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/102,103\">",
"       102,103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCA16 is now thought to be the same disorder as SCA15 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/104,105\">",
"       104,105",
"      </a>",
"      ]. It was originally identified as an autosomal dominant cerebellar ataxia in a four-generation Japanese family [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/99,106\">",
"       99,106",
"      </a>",
"      ]. While initial linkage analysis suggested the locus was on chromosome 8q22.1-24.1 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/99\">",
"       99",
"      </a>",
"      ], a later analysis suggested that SCA16 links with 3p26.2pter, a region that partly overlaps the SCA15 region [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/106\">",
"       106",
"      </a>",
"      ]. A heterozygous deletion in the ITPR1 gene, the causative gene for SCA 15, was then demonstrated in a family SCA16, confirming that SCA16 is the same disorder as SCA15 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCA17 is an autosomal dominant cerebellar ataxia described in four Japanese pedigrees [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/107\">",
"       107",
"      </a>",
"      ]. It is caused by an abnormal CAG expansion in the TATA-binding protein (TBP) gene, a general transcription initiation factor. The age of onset ranges from 19 to 48 years and is inversely related to the number of CAG repeats in the TBP gene (4 to 35 normally, 37 to over 200 on mutant alleles). Most individuals present between the ages of 20 and 30 with gait ataxia and dementia, progressing over several decades to include bradykinesia, dysmetria, dysdiadochokinesis, hyperreflexia, and paucity of movement. One family with SCA17 has been described with a Huntington disease-like syndrome, including generalized chorea [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/108\">",
"       108",
"      </a>",
"      ]. Diffuse cortical and cerebellar atrophy is present on neuroimaging in all patients.",
"      <br/>",
"      <br/>",
"      Mouse models of SCA17 have been generated by expressing TBP with expanded polyglutamine tracts under the mouse prion promoter. These mice demonstrate a neurodegenerative syndrome. Moreover, biochemical experiments suggest that the expanded polyglutamine tracts reduce TBP dimerization but enhance the interaction of TBP with the general transcription factor IIB, implicating the polyglutamine domain of TBP in transcriptional regulation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCA18 is an autosomal dominant disorder described in an American family of Irish ancestry with ataxia, pyramidal tract signs, muscle weakness, sensory axonal neuropathy, and mild cerebellar atrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/110\">",
"       110",
"      </a>",
"      ]. Haplotype analysis links the disorder to a region at 7q22-q32.",
"     </li>",
"     <li>",
"      Both SCA19, originally identified in a Dutch family [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/111,112\">",
"       111,112",
"      </a>",
"      ], and SCA22, originally identified in a Taiwanese family [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/113\">",
"       113",
"      </a>",
"      ], are autosomal dominant allelic conditions caused by mutations in the KCND3 gene that encodes for Kv4.3, a voltage-gated potassium channel [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/114-116\">",
"       114-116",
"      </a>",
"      ].",
"      <span class=\"nowrap\">",
"       SCA19/22",
"      </span>",
"      has been identified in multiple unrelated families of diverse ethnic origins. The phenotype is predominantly a cerebellar syndrome, but more severe cases can be associated with cognitive impairment or myoclonus.",
"     </li>",
"     <li>",
"      SCA20 is described in a family of Anglo-Celtic origin with a slowly progressive, autosomal dominant SCA [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/117\">",
"       117",
"      </a>",
"      ]. Age of onset in 14 family members was 19 to 64 years (mean 46.5). Dysarthria is the most common initial symptom. Gait or upper limb ataxia follows in most. Palatal tremor and dysphonia are distinguishing clinical features. Dentate nucleus calcification can be visualized by brain imaging with CT or MRI. The disease locus maps to chromosome 11.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     SCA types 21 to 36",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional rare types of SCA include those numbered from 21 through 36.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SCA21 is identified in a four generation French family [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/118\">",
"       118",
"      </a>",
"      ]. Manifestations include gait ataxia and akinesia, with variable features of dysarthria, hyporeflexia, and mild cognitive impairment. The responsible locus maps to chromosome 7p21.3-p15.1 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/119\">",
"       119",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As noted above, SCA22 and SCA19 are allelic conditions identified in multiple unrelated families of diverse ethnic origins. The phenotype is predominantly a cerebellar syndrome, but more severe cases can be associated with cognitive impairment or myoclonus.",
"      <span class=\"nowrap\">",
"       SCA19/22",
"      </span>",
"      is caused by mutations in the KCND3 gene that encodes for Kv4.3, a voltage-gated potassium channel [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/114-116\">",
"       114-116",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCA23 is described in a Dutch family and is characterized by a late-onset (age &gt;40 years), slowly progressive, SCA with variable dysarthria, ocular dysmetria, and distal sensory deficits [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/120\">",
"       120",
"      </a>",
"      ]. Mutations in the PDYN gene located on chromosome region 20p13 are causative [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/121\">",
"       121",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCA24 is a recessively inherited ataxia, and has been redesignated as SCAR4. This condition is described in a Slovenian family with progressive ataxia and disruption of visual fixation by large horizontal saccadic intrusions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/122,123\">",
"       122,123",
"      </a>",
"      ]. Corticospinal signs and an axonal sensorimotor neuropathy are additional manifestations. The disorder is due to a mutation on chromosome region 1p36.",
"     </li>",
"     <li>",
"      SCA25 is described in a large French family and is characterized by cerebellar ataxia and sensory neuropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/124\">",
"       124",
"      </a>",
"      ]. The responsible locus maps to chromosome 2. The phenotype is highly variable regarding age of onset, severity and clinical manifestations, ranging from infantile-onset cerebellar ataxia with pure sensory neuropathy, suggestive of Friedreich's ataxia, to a form with mild cerebellar ataxia and prominent sensory neuropathy suggestive of Charcot-Marie-Tooth.",
"     </li>",
"     <li>",
"      SCA26 is described in a Norwegian family and is characterized by a pure slowly progressive cerebellar ataxia with autosomal dominant inheritance [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/125\">",
"       125",
"      </a>",
"      ]. The genetic locus maps to chromosome 19p13.3 and is adjacent to the locus responsible for SCA6.",
"     </li>",
"     <li>",
"      SCA27 is described in a large Dutch family and is characterized by early-onset tremor, dyskinesia, slowly progressive cerebellar ataxia, cognitive impairment, and a mutation in the fibroblast growth factor 14 (FGF14) gene on chromosome 13q34. [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/126,127\">",
"       126,127",
"      </a>",
"      ]. A mutation in FGF14 has also been reported in a German patient with familial ataxia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/128\">",
"       128",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCA28 is described in an Italian family and is characterized by a juvenile-onset (mean age 19.5 years), slowly progressive cerebellar ataxia with eye movement abnormalities and, in some cases, pyramidal tract signs [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/129\">",
"       129",
"      </a>",
"      ]. Inheritance is autosomal dominant. The disorder is caused by heterozygous missense mutations in the mitochondrial protease gene AFG3L2 that maps to chromosome region 18p11 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/130\">",
"       130",
"      </a>",
"      ]. Intriguingly, the protein encoded by this gene is a homologue of paraplegin, a protein mutated in one form of hereditary spastic paraplegia (SPG7).",
"     </li>",
"     <li>",
"      SCA29 maps to chromosome 3p26 and may be an allelic variant of SCA15 described above [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/131\">",
"       131",
"      </a>",
"      ]. It is characterized by autosomal dominant inheritance and clinically by early onset, nonprogressive ataxia with variable atrophy of the cerebellar vermis.",
"     </li>",
"     <li>",
"      SCA30 is an autosomal dominant form described in an Australian family of Anglo-Celtic origin [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/132\">",
"       132",
"      </a>",
"      ]. Clinical features include onset in mid to late life of a slowly progressive, relatively pure ataxia with hypermetric saccades and minor pyramidal signs. Brain MRI shows atrophy of the cerebellar vermis and cerebellar hemisphere. The disorder maps to chromosome 4q34.3-q35.1. While the responsible gene is not established, the ODZ3 gene is a candidate.",
"     </li>",
"     <li>",
"      SCA31, previously called 16q22-linked autosomal dominant spinocerebellar ataxia, is characterized in Japanese populations by late onset cerebellar ataxia and reduced muscle tone with or without sensorineural hearing loss [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/133-135\">",
"       133-135",
"      </a>",
"      ]. Its locus is on chromosome 16q22.1, close to SCA4. It is caused by an insertion containing pentanucleotide repeats, including a long (TGGAA)n sequence, within an intronic region shared by the TK2 and BEAN genes [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/136\">",
"       136",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCA32 is described in a single Chinese family with autosomal dominant ataxia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/137\">",
"       137",
"      </a>",
"      ]. Cognitive impairment affects those with onset before age 40. All males are infertile due to azoospermia. The disorder links to a locus on chromosome 7q32-q33.",
"     </li>",
"     <li>",
"      SCA33 has not been assigned to a clinical disorder.",
"     </li>",
"     <li>",
"      SCA34 is reported in a French Canadian kindred with autosomal dominant SCA and skin lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/138\">",
"       138",
"      </a>",
"      ]. The condition maps to a locus on chromosome 6p12.3-q16.2 [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/139\">",
"       139",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SCA35 is described in a single Chinese family [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/140\">",
"       140",
"      </a>",
"      ]. Onset is at a mean age of 44 years, and the disorder is notable for slowly progressive gait and limb ataxia and mild dysarthria. SCA35 is caused by heterozygous mutations in the TGM6 gene located on chromosome 20p13.",
"     </li>",
"     <li>",
"      SCA36 is reported in a number of families from Japan [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/141-143\">",
"       141-143",
"      </a>",
"      ] and Spain [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/144\">",
"       144",
"      </a>",
"      ]. The clinical features include late-onset (mean age of 53 years in Japan) with cerebellar dysfunction manifesting as truncal ataxia, dysarthria, and limb ataxia. Motor neuron involvement occurred in most patients from Japan with longer disease duration [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/141,142\">",
"       141,142",
"      </a>",
"      ], while sensorineural hearing loss occurred as an early feature in most cases from Spain [",
"      <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/144\">",
"       144",
"      </a>",
"      ]. SCA36 is caused by expansion of an intronic GGCCTG hexanucleotide repeat in the NOP56 gene located on chromosome 20p13.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DISORDERS THAT RESEMBLE SCA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three other autosomal dominant ataxic disorders may resemble the SCAs: dentatorubral pallidoluysian atrophy, fragile X associated tremor ataxia syndrome, and prion disorders. In addition, episodic ataxias are dominantly inherited and are discussed here briefly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Dentatorubral pallidoluysian atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dentatorubral pallidoluysian atrophy (DRPLA) should be suspected when ataxia and rigidity are accompanied by choreoathetosis, myoclonic epilepsy, and dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/145,146\">",
"     145,146",
"    </a>",
"    ]. Other features include hyperreflexia and slowing of saccades. MRI or CT scan often reveals atrophy of the cerebellum and brainstem, calcification of the basal ganglia, and leukodystrophic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DRPLA is a disease that is relatively common in Japan. Most reports suggest that DRPLA is rare in Caucasian populations in Europe and North America [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/148-150\">",
"     148-150",
"    </a>",
"    ], but data are conflicting, and one study found it to be an important cause of late-onset cerebellar ataxia in Wales [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DRPLA is caused by CAG tract expansion of 49 to 88 repeats on chromosome 12p and presents with anticipation, especially when transmission is via the father [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/145,152\">",
"     145,152",
"    </a>",
"    ]. Normal CAG tracts in DRPLA bear 6 to 35 repeats. The product of the DRPLA gene is a cytoplasmic protein called atrophin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/153\">",
"     153",
"    </a>",
"    ]. The action of other enzymes on mutant atrophin-1, such as transglutaminase and caspase, may be involved in the neurotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/154,155\">",
"     154,155",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Haw River syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Haw-River syndrome, a variant of DRPLA without the characteristic myoclonic epilepsy, has been described in a few families of African-American descent in North Carolina. It is caused by the same expanded repeat as DRPLA [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/156\">",
"     156",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fragile X-associated tremor/ataxia syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fragile X-associated",
"    <span class=\"nowrap\">",
"     tremor/ataxia",
"    </span>",
"    syndrome (FXTAS) occurs mainly in older men who are carriers of a premutation in the fragile X mental retardation 1 gene (FMR1) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/157-159\">",
"     157-159",
"    </a>",
"    ]. The premutation consists of a trinucleotide CGG repeat length ranging from 50 to 200 in the FMR1 gene.",
"   </p>",
"   <p>",
"    Fragile X syndrome is caused by a trinucleotide CGG expansion typically greater than 200 in the same FMR1 gene. It is a common genetic cause of mental retardation in males [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/160\">",
"     160",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=see_link&amp;anchor=H16#H16\">",
"     \"Genetic and environmental causes of birth defects\", section on 'Unstable DNA and fragile X syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carriers of the FMR1 gene premutation who have repeat lengths of 55 to 200 do not have the more severe neurodevelopmental problems associated with the full mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/161\">",
"     161",
"    </a>",
"    ]. However, premutation carriers can present with one or more of the following three clinical syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/162\">",
"     162",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Premature ovarian failure",
"     </li>",
"     <li>",
"      Fragile X associated tremor-ataxia syndrome (FXTAS)",
"     </li>",
"     <li>",
"      Mild cognitive and behavioral deficits on the spectrum of those seen in fragile X syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 20 to 33 percent of adult male premutation carriers display the FXTAS phenotype, and the prevalence of the premutation carrier state is as high as one in 813 males, suggesting that FXTAS is a frequent genetic cause of ataxia in older men [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/163\">",
"     163",
"    </a>",
"    ]. Both increasing age and larger CGG expansions in premutation carriers are associated with greater motor impairment as assessed by severity of tremor, ataxia, and parkinsonism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/164\">",
"     164",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although FXTAS was initially thought to affect only male premutation carriers, subsequent reports have described the development of FXTAS in women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/165,166\">",
"     165,166",
"    </a>",
"    ], related at least in part to X-inactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/167\">",
"     167",
"    </a>",
"    ]. Women are less likely than men to develop FXTAS, and those who do have milder disease than men, because female premutation carriers are relatively protected from the disease by the presence of a normal X chromosome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/165\">",
"     165",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The molecular mechanism causing FXTAS differs from that causing the fragile X syndrome. In fragile X syndrome, methylation of DNA sequences in the promoter where the expanded CGG resides causes silencing of the FMR1 gene and complete loss of FMR1 protein. In FXTAS, fragile X RNA is produced but it is poorly translated into protein. This translational deficit is thought to cause a compensatory increase in the levels of FMR1 transcripts. Unfortunately, the RNA bearing the expansion now causes a toxic gain-of-function effect triggering downstream protein accumulation and neurodegeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/161\">",
"     161",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant clinical features of FXTAS are a late-onset ataxia associated with postural tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/157-159\">",
"     157-159",
"    </a>",
"    ]. Additional clinical features of FXTAS can include short-term memory loss, executive function deficits, cognitive decline, parkinsonism, peripheral neuropathy, lower limb proximal muscle weakness, and autonomic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/161,168\">",
"     161,168",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Brain atrophy and characteristic high signal lesions in the middle cerebellar peduncle and splenium of the corpus callosum can be seen with brain MRI using T2 and FLAIR sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/159,169,170\">",
"     159,169,170",
"    </a>",
"    ]. White matter disease associated with astrocytic pathology is seen on neuropathologic examination, and intranuclear inclusions are present in both neurons and astrocytes in brain and spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/171\">",
"     171",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Misdiagnosis of FXTAS may be common. This point is illustrated by a study of 56 patients with FXTAS and a family history of fragile X syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/172\">",
"     172",
"    </a>",
"    ]. These patients received a wide variety of prior diagnoses other than FXTAS as an explanation for their symptoms, including various types of parkinsonism, tremor, ataxia, dementia, and cerebrovascular disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     FMR1 DNA testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for the FMR1 premutation in patients who have neurologic illnesses, such as Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/173\">",
"     173",
"    </a>",
"    ], essential tremor [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/174\">",
"     174",
"    </a>",
"    ], or multiple systems atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/175\">",
"     175",
"    </a>",
"    ], has a very low yield. Screening in older men with late onset cerebellar ataxia may be more fruitful [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/163\">",
"     163",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on proposed guidelines for genetic confirmation of FXTAS, testing for FMR1 is suggested for patients who have either of the following presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/172,176\">",
"     172,176",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unexplained cerebellar ataxia in men older than age 50",
"     </li>",
"     <li>",
"      Presence of action tremor, parkinsonism, or dementia in men older than age 50 with additionally either a family history of developmental delay, autism, mental retardation, or premature ovarian failure, or the middle cerebellar peduncle sign on brain MRI",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Gerstmann-Str&auml;ussler-Scheinker syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prion diseases, particularly the ataxic variant of the Gerstmann-Str&auml;ussler-Scheinker (GSS) syndrome, can mimic a spinocerebellar syndrome. GSS is diagnosed when autosomal dominant ataxia coexists with cognitive and motor decline plus pathologic findings of prion protein-containing amyloid plaques. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=see_link\">",
"     \"Diseases of the central nervous system caused by prions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    GSS results from mutations in the PRNP gene. The ataxic variant of GSS is caused by a proline to leucine missense at codon 102 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/177\">",
"     177",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7017?source=see_link&amp;anchor=H12#H12\">",
"     \"Biology and genetics of prions\", section on 'Gerstmann-Str&auml;ussler-Scheinker syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     EVALUATION OF THE PATIENT WITH AUTOSOMAL DOMINANT ATAXIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the types of autosomal dominant ataxia have clinical features that may be suggestive of that disorder (",
"    <a class=\"graphic graphic_table graphicRef74269 \" href=\"UTD.htm?10/59/11198\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of a patient who has a positive family history of cerebellar ataxia, genetic testing is the most efficient and definitive way to determine the cause of the symptoms and to identify the ataxia subtype. The few clinical differentiating features (",
"    <a class=\"graphic graphic_table graphicRef74269 \" href=\"UTD.htm?10/59/11198\">",
"     table 1",
"    </a>",
"    ) may suggest the likely candidate(s) for a step-wise screen.",
"   </p>",
"   <p>",
"    In most cases, however, a blood sample is tested for mutations in all the known SCA-causing genes at once. This list includes SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10, SCA17, and DRPLA. It is likely to expand as more genes are discovered or as novel phenotypes of other genetic defects are discovered; this has been the case with the fragile X premutation. Online resources (eg,",
"    <a class=\"external\" href=\"file://www.geneclinics.org/\">",
"     www.geneclinics.org",
"    </a>",
"    ) can be used to determine which types can be tested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional studies are warranted if genetic testing is not revealing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if a question exists about a co-existing disease process. Neuroimaging with MRI or CT scan often reveals the typical cerebellar atrophy. Ruling out other causes of ataxia including space occupying lesions, demyelinating, or vascular events, also is important.",
"   </p>",
"   <p>",
"    Among the spinocerebellar ataxias, atrophy is most prominent in SCA2 and least prominent in the milder diseases, SCA5 and SCA6. Brainstem atrophy, which would be expected to be almost universal, is characteristic of SCA1, SCA2, and SCA7. In one study, the degree of atrophy correlated with the neurologic deficit in SCA1 but not SCA2 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/35/29242/abstract/178\">",
"     178",
"    </a>",
"    ]. Brainstem atrophy is minimal in SCA3 and DRPLA, and is rare in SCA6. Cerebral atrophy with compensatory enlargement of the lateral ventricles can be seen in SCA2, the infantile variant of SCA7, and DRPLA.",
"   </p>",
"   <p>",
"    Less widely used and more expensive imaging studies such as magnetic resonance spectroscopy and positron emission tomography (PET) scanning are sensitive markers for deterioration and can demonstrate abnormalities not seen on MRI. At present, however, these modalities should be reserved for research rather than diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Electrophysiologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most spinocerebellar ataxias cause defects in nerve conduction, especially SCA4. The predominant axonal neuropathy primarily affects sensory neurons, and sural nerve action potentials often are absent. However, these studies are rarely useful in determining the type of ataxia. On the other hand, visual-evoked potentials may suggest SCA7 because of the characteristic macular degeneration, whereas interictal electroencephalographic (EEG) abnormalities may suggest DRPLA. Seizures also are common in SCA10, but the interictal EEG is typically normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99235102\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spinocerebellar ataxias (SCA) are classified according to the genetic loci of the SCA. These loci have been numbered according to their order of identification: SCA1 through SCA36 (and the number continues to grow). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cerebellar ataxia is a feature of each type of SCA. Other distinguishing features may suggest a particular type (",
"      <a class=\"graphic graphic_table graphicRef74269 \" href=\"UTD.htm?10/59/11198\">",
"       table 1",
"      </a>",
"      ). However, only 60 to 75 percent of patients with SCA have mutations in the known loci. Furthermore, among patients with apparently idiopathic sporadic cerebellar ataxia (ie, no family history), an SCA mutation (types 1, 2, 3, 6, 7, 8, or 12), most often SCA6, or Friedreich ataxia, can be identified in approximately 20 percent. Several types of spinocerebellar ataxias (SCA1, 2, 3, 6, 7, and 17) are associated with expansion of CAG repeats in the region that encodes for polyglutamine tracts in the protein products. They typically present in middle age, with progressive ataxia, neuronal dysfunction and eventual neuronal loss during the ensuing 10 to 20 years. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Overview of SCA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The age of onset and rate of disability progression for the more common SCAs vary according to individual differences in the length of the causative CAG trinucleotide repeat. Most of the available data concern SCA1, SCA1, SCA3, and SCA6, which are the four most common types. In these disorders, most patients require a wheelchair by 10 to 15 years after symptom onset. Disability and mortality data for the other types of SCAs are limited. No effective treatment is available. (See",
"      <a class=\"local\" href=\"#H605308128\">",
"       'Prognosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCA3, also known as Machado-Joseph disease, is the most common type of SCA (",
"      <a class=\"graphic graphic_table graphicRef74269 \" href=\"UTD.htm?10/59/11198\">",
"       table 1",
"      </a>",
"      ). SCA types 9 through 36 are rare and less well characterized. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Classification of SCA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other autosomal dominant ataxic disorders that resemble SCA include dentatorubral pallidoluysian atrophy, fragile X-associated",
"      <span class=\"nowrap\">",
"       tremor/ataxia",
"      </span>",
"      syndrome, and prion disorders, particularly the ataxic variant of the Gerstmann-Str&auml;ussler-Scheinker syndrome. In addition, episodic ataxias are dominantly inherited. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Disorders that resemble SCA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the setting of a patient who has a positive family history of cerebellar ataxia, genetic testing is the most efficient and definitive way to determine the cause of the symptoms and to identify the ataxia subtype. Additional studies are warranted if genetic testing is not revealing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      if a question exists about a co-existing disease process. Neuroimaging with MRI or CT scan often reveals the typical cerebellar atrophy. Ruling out other causes of ataxia including space occupying lesions, demyelinating, or vascular events, also is important. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Evaluation of the patient with autosomal dominant ataxia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/1\">",
"      Harding AE. Clinical features and classification of inherited ataxias. Adv Neurol 1993; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/2\">",
"      Manto MU. The wide spectrum of spinocerebellar ataxias (SCAs). Cerebellum 2005; 4:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/3\">",
"      Sch&ouml;ls L, Szymanski S, Peters S, et al. Genetic background of apparently idiopathic sporadic cerebellar ataxia. Hum Genet 2000; 107:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/4\">",
"      Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 1995; 378:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/5\">",
"      Jacobi H, Bauer P, Giunti P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology 2011; 77:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/6\">",
"      R&uuml;b U, B&uuml;rk K, Sch&ouml;ls L, et al. Damage to the reticulotegmental nucleus of the pons in spinocerebellar ataxia type 1, 2, and 3. Neurology 2004; 63:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/7\">",
"      Klockgether T, L&uuml;dtke R, Kramer B, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 1998; 121 ( Pt 4):589.",
"     </a>",
"    </li>",
"    <li>",
"     Bird TD. Hereditary ataxia overview. In: GeneReviews [Internet]. www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=ataxias (Accessed on September 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/9\">",
"      Clauss R, Sathekge M, Nel W. Transient improvement of spinocerebellar ataxia with zolpidem. N Engl J Med 2004; 351:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/10\">",
"      Zesiewicz TA, Greenstein PE, Sullivan KL, et al. A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology 2012; 78:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/11\">",
"      Cummings CJ, Mancini MA, Antalffy B, et al. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet 1998; 19:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/12\">",
"      Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000; 287:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/13\">",
"      Warrick JM, Chan HY, Gray-Board GL, et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet 1999; 23:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/14\">",
"      Xia H, Mao Q, Eliason SL, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/15\">",
"      Orr HT, Chung MY, Banfi S, et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 1993; 4:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/16\">",
"      Skinner PJ, Koshy BT, Cummings CJ, et al. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 1997; 389:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/17\">",
"      Chai Y, Koppenhafer SL, Shoesmith SJ, et al. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro. Hum Mol Genet 1999; 8:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/18\">",
"      Cummings CJ, Reinstein E, Sun Y, et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 1999; 24:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/19\">",
"      Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998; 95:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/20\">",
"      Klement IA, Skinner PJ, Kaytor MD, et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998; 95:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/21\">",
"      Lin X, Antalffy B, Kang D, et al. Polyglutamine expansion down-regulates specific neuronal genes before pathologic changes in SCA1. Nat Neurosci 2000; 3:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/22\">",
"      Chong SS, McCall AE, Cota J, et al. Gametic and somatic tissue-specific heterogeneity of the expanded SCA1 CAG repeat in spinocerebellar ataxia type 1. Nat Genet 1995; 10:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/23\">",
"      Matilla A, Koshy BT, Cummings CJ, et al. The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 1997; 389:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/24\">",
"      Emamian ES, Kaytor MD, Duvick LA, et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 2003; 38:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/25\">",
"      Chen HK, Fernandez-Funez P, Acevedo SF, et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 2003; 113:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/26\">",
"      Tang B, Liu C, Shen L, et al. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. Arch Neurol 2000; 57:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/27\">",
"      Ranum LP, Lundgren JK, Schut LJ, et al. Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia. Am J Hum Genet 1995; 57:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/28\">",
"      Geschwind DH, Perlman S, Figueroa CP, et al. The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. Am J Hum Genet 1997; 60:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/29\">",
"      Moseley ML, Benzow KA, Schut LJ, et al. Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology 1998; 51:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/30\">",
"      Storey E, du Sart D, Shaw JH, et al. Frequency of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Australian patients with spinocerebellar ataxia. Am J Med Genet 2000; 95:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/31\">",
"      Lorenzetti D, Bohlega S, Zoghbi HY. The expansion of the CAG repeat in ataxin-2 is a frequent cause of autosomal dominant spinocerebellar ataxia. Neurology 1997; 49:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/32\">",
"      Orozco Diaz G, Nodarse Fleites A, Cordov&eacute;s Sagaz R, Auburger G. Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holgu&iacute;n, Cuba. Neurology 1990; 40:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/33\">",
"      Pulst SM, Nechiporuk A, Nechiporuk T, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996; 14:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/34\">",
"      Sanpei K, Takano H, Igarashi S, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 1996; 14:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/35\">",
"      Huynh DP, Figueroa K, Hoang N, Pulst SM. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet 2000; 26:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/36\">",
"      Imbert G, Saudou F, Yvert G, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 1996; 14:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/37\">",
"      Babovic-Vuksanovic D, Snow K, Patterson MC, Michels VV. Spinocerebellar ataxia type 2 (SCA 2) in an infant with extreme CAG repeat expansion. Am J Med Genet 1998; 79:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/38\">",
"      Paciorkowski AR, Shafrir Y, Hrivnak J, et al. Massive expansion of SCA2 with autonomic dysfunction, retinitis pigmentosa, and infantile spasms. Neurology 2011; 77:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/39\">",
"      Fernandez M, McClain ME, Martinez RA, et al. Late-onset SCA2: 33 CAG repeats are sufficient to cause disease. Neurology 2000; 55:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/40\">",
"      Vel&aacute;zquez-P&eacute;rez L, Seifried C, Santos-Falc&oacute;n N, et al. Saccade velocity is controlled by polyglutamine size in spinocerebellar ataxia 2. Ann Neurol 2004; 56:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/41\">",
"      Gwinn-Hardy K, Chen JY, Liu HC, et al. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 2000; 55:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/42\">",
"      Malandrini A, Galli L, Villanova M, et al. CAG repeat expansion in an italian family with spinocerebellar ataxia type 2 (SCA2): a clinical and genetic study. Eur Neurol 1998; 40:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/43\">",
"      Belal S, Cancel G, Stevanin G, et al. Clinical and genetic analysis of a Tunisian family with autosomal dominant cerebellar ataxia type 1 linked to the SCA2 locus. Neurology 1994; 44:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/44\">",
"      D&uuml;rr A, Smadja D, Cancel G, et al. Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families. Brain 1995; 118 ( Pt 6):1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/45\">",
"      Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994; 8:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/46\">",
"      Higgins JJ, Nee LE, Vasconcelos O, et al. Mutations in American families with spinocerebellar ataxia (SCA) type 3: SCA3 is allelic to Machado-Joseph disease. Neurology 1996; 46:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/47\">",
"      Tait D, Riccio M, Sittler A, et al. Ataxin-3 is transported into the nucleus and associates with the nuclear matrix. Hum Mol Genet 1998; 7:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/48\">",
"      Warrick JM, Paulson HL, Gray-Board GL, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998; 93:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/49\">",
"      Ikeda H, Yamaguchi M, Sugai S, et al. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet 1996; 13:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/50\">",
"      Fran&ccedil;a MC Jr, D'Abreu A, Nucci A, Lopes-Cendes I. Muscle excitability abnormalities in Machado-Joseph disease. Arch Neurol 2008; 65:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/51\">",
"      Kawai Y, Takeda A, Abe Y, et al. Cognitive impairments in Machado-Joseph disease. Arch Neurol 2004; 61:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/52\">",
"      Yeh TH, Lu CS, Chou YH, et al. Autonomic dysfunction in Machado-Joseph disease. Arch Neurol 2005; 62:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/53\">",
"      Flanigan K, Gardner K, Alderson K, et al. Autosomal dominant spinocerebellar ataxia with sensory axonal neuropathy (SCA4): clinical description and genetic localization to chromosome 16q22.1. Am J Hum Genet 1996; 59:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/54\">",
"      Nagaoka U, Takashima M, Ishikawa K, et al. A gene on SCA4 locus causes dominantly inherited pure cerebellar ataxia. Neurology 2000; 54:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/55\">",
"      Stevanin G, Herman A, Brice A, D&uuml;rr A. Clinical and MRI findings in spinocerebellar ataxia type 5. Neurology 1999; 53:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/56\">",
"      Ranum LP, Schut LJ, Lundgren JK, et al. Spinocerebellar ataxia type 5 in a family descended from the grandparents of President Lincoln maps to chromosome 11. Nat Genet 1994; 8:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/57\">",
"      Ikeda Y, Dick KA, Weatherspoon MR, et al. Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet 2006; 38:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/58\">",
"      Gomez CM, Thompson RM, Gammack JT, et al. Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset. Ann Neurol 1997; 42:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/59\">",
"      Stevanin G, D&uuml;rr A, David G, et al. Clinical and molecular features of spinocerebellar ataxia type 6. Neurology 1997; 49:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/60\">",
"      Matsumura R, Futamura N, Fujimoto Y, et al. Spinocerebellar ataxia type 6. Molecular and clinical features of 35 Japanese patients including one homozygous for the CAG repeat expansion. Neurology 1997; 49:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/61\">",
"      Craig K, Keers SM, Archibald K, et al. Molecular epidemiology of spinocerebellar ataxia type 6. Ann Neurol 2004; 55:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/62\">",
"      Zhuchenko O, Bailey J, Bonnen P, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 1997; 15:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/63\">",
"      Restituito S, Thompson RM, Eliet J, et al. The polyglutamine expansion in spinocerebellar ataxia type 6 causes a beta subunit-specific enhanced activation of P/Q-type calcium channels in Xenopus oocytes. J Neurosci 2000; 20:6394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/64\">",
"      Ishikawa K, Fujigasaki H, Saegusa H, et al. Abundant expression and cytoplasmic aggregations of [alpha]1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6. Hum Mol Genet 1999; 8:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/65\">",
"      Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/66\">",
"      Terwindt GM, Ophoff RA, Haan J, et al. Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine. Dutch Migraine Genetics Research Group. Neurology 1998; 50:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/67\">",
"      Benton CS, de Silva R, Rutledge SL, et al. Molecular and clinical studies in SCA-7 define a broad clinical spectrum and the infantile phenotype. Neurology 1998; 51:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/68\">",
"      Ansorge O, Giunti P, Michalik A, et al. Ataxin-7 aggregation and ubiquitination in infantile SCA7 with 180 CAG repeats. Ann Neurol 2004; 56:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/69\">",
"      Gouw LG, Kaplan CD, Haines JH, et al. Retinal degeneration characterizes a spinocerebellar ataxia mapping to chromosome 3p. Nat Genet 1995; 10:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/70\">",
"      David G, Abbas N, Stevanin G, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet 1997; 17:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/71\">",
"      Stevanin G, Giunti P, Belal GD, et al. De novo expansion of intermediate alleles in spinocerebellar ataxia 7. Hum Mol Genet 1998; 7:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/72\">",
"      Lindenberg KS, Yvert G, M&uuml;ller K, Landwehrmeyer GB. Expression analysis of ataxin-7 mRNA and protein in human brain: evidence for a widespread distribution and focal protein accumulation. Brain Pathol 2000; 10:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/73\">",
"      Yvert G, Lindenberg KS, Picaud S, et al. Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum Mol Genet 2000; 9:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/74\">",
"      Day JW, Schut LJ, Moseley ML, et al. Spinocerebellar ataxia type 8: clinical features in a large family. Neurology 2000; 55:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/75\">",
"      Juvonen V, Hietala M, P&auml;iv&auml;rinta M, et al. Clinical and genetic findings in Finnish ataxia patients with the spinocerebellar ataxia 8 repeat expansion. Ann Neurol 2000; 48:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/76\">",
"      Ito H, Kawakami H, Wate R, et al. Clinicopathologic investigation of a family with expanded SCA8 CTA/CTG repeats. Neurology 2006; 67:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/77\">",
"      Todd PK, Paulson HL. RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol 2010; 67:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/78\">",
"      Koob MD, Moseley ML, Schut LJ, et al. An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). Nat Genet 1999; 21:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/79\">",
"      Silveira I, Alonso I, Guimar&atilde;es L, et al. High germinal instability of the (CTG)n at the SCA8 locus of both expanded and normal alleles. Am J Hum Genet 2000; 66:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/80\">",
"      Moseley ML, Zu T, Ikeda Y, et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat Genet 2006; 38:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/81\">",
"      Ikeda Y, Dalton JC, Moseley ML, et al. Spinocerebellar ataxia type 8: molecular genetic comparisons and haplotype analysis of 37 families with ataxia. Am J Hum Genet 2004; 75:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/82\">",
"      Grewal RP, Achari M, Matsuura T, et al. Clinical features and ATTCT repeat expansion in spinocerebellar ataxia type 10. Arch Neurol 2002; 59:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/83\">",
"      Teive HA, Roa BB, Raskin S, et al. Clinical phenotype of Brazilian families with spinocerebellar ataxia 10. Neurology 2004; 63:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/84\">",
"      Gatto EM, Gao R, White MC, et al. Ethnic origin and extrapyramidal signs in an Argentinean spinocerebellar ataxia type 10 family. Neurology 2007; 69:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/85\">",
"      Matsuura T, Achari M, Khajavi M, et al. Mapping of the gene for a novel spinocerebellar ataxia with pure cerebellar signs and epilepsy. Ann Neurol 1999; 45:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/86\">",
"      Zu L, Figueroa KP, Grewal R, Pulst SM. Mapping of a new autosomal dominant spinocerebellar ataxia to chromosome 22. Am J Hum Genet 1999; 64:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/87\">",
"      Matsuura T, Yamagata T, Burgess DL, et al. Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet 2000; 26:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/88\">",
"      Worth PF, Giunti P, Gardner-Thorpe C, et al. Autosomal dominant cerebellar ataxia type III: linkage in a large British family to a 7.6-cM region on chromosome 15q14-21.3. Am J Hum Genet 1999; 65:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/89\">",
"      Houlden H, Johnson J, Gardner-Thorpe C, et al. Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nat Genet 2007; 39:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/90\">",
"      Holmes SE, O'Hearn EE, McInnis MG, et al. Expansion of a novel CAG trinucleotide repeat in the 5' region of PPP2R2B is associated with SCA12. Nat Genet 1999; 23:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/91\">",
"      Herman-Bert A, Stevanin G, Netter JC, et al. Mapping of spinocerebellar ataxia 13 to chromosome 19q13.3-q13.4 in a family with autosomal dominant cerebellar ataxia and mental retardation. Am J Hum Genet 2000; 67:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/92\">",
"      Waters MF, Minassian NA, Stevanin G, et al. Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat Genet 2006; 38:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/93\">",
"      Yamashita I, Sasaki H, Yabe I, et al. A novel locus for dominant cerebellar ataxia (SCA14) maps to a 10.2-cM interval flanked by D19S206 and D19S605 on chromosome 19q13.4-qter. Ann Neurol 2000; 48:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/94\">",
"      Yabe I, Sasaki H, Chen DH, et al. Spinocerebellar ataxia type 14 caused by a mutation in protein kinase C gamma. Arch Neurol 2003; 60:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/95\">",
"      Verbeek DS, Knight MA, Harmison GG, et al. Protein kinase C gamma mutations in spinocerebellar ataxia 14 increase kinase activity and alter membrane targeting. Brain 2005; 128:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/96\">",
"      Chen DH, Cimino PJ, Ranum LP, et al. The clinical and genetic spectrum of spinocerebellar ataxia 14. Neurology 2005; 64:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/97\">",
"      Klebe S, Durr A, Rentschler A, et al. New mutations in protein kinase Cgamma associated with spinocerebellar ataxia type 14. Ann Neurol 2005; 58:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/98\">",
"      Storey E, Gardner RJ, Knight MA, et al. A new autosomal dominant pure cerebellar ataxia. Neurology 2001; 57:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/99\">",
"      Miyoshi Y, Yamada T, Tanimura M, et al. A novel autosomal dominant spinocerebellar ataxia (SCA16) linked to chromosome 8q22.1-24.1. Neurology 2001; 57:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/100\">",
"      Knight MA, Kennerson ML, Anney RJ, et al. Spinocerebellar ataxia type 15 (sca15) maps to 3p24.2-3pter: exclusion of the ITPR1 gene, the human orthologue of an ataxic mouse mutant. Neurobiol Dis 2003; 13:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/101\">",
"      Hara K, Fukushima T, Suzuki T, et al. Japanese SCA families with an unusual phenotype linked to a locus overlapping with SCA15 locus. Neurology 2004; 62:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/102\">",
"      van de Leemput J, Chandran J, Knight MA, et al. Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet 2007; 3:e108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/103\">",
"      Hara K, Shiga A, Nozaki H, et al. Total deletion and a missense mutation of ITPR1 in Japanese SCA15 families. Neurology 2008; 71:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/104\">",
"      Iwaki A, Kawano Y, Miura S, et al. Heterozygous deletion of ITPR1, but not SUMF1, in spinocerebellar ataxia type 16. J Med Genet 2008; 45:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/105\">",
"      Gardner RJ. \"SCA16\" is really SCA15. J Med Genet 2008; 45:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/106\">",
"      Miura S, Shibata H, Furuya H, et al. The contactin 4 gene locus at 3p26 is a candidate gene of SCA16. Neurology 2006; 67:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/107\">",
"      Nakamura K, Jeong SY, Uchihara T, et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001; 10:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/108\">",
"      Schneider SA, van de Warrenburg BP, Hughes TD, et al. Phenotypic homogeneity of the Huntington disease-like presentation in a SCA17 family. Neurology 2006; 67:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/109\">",
"      Friedman MJ, Shah AG, Fang ZH, et al. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat Neurosci 2007; 10:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/110\">",
"      Brkanac Z, Fernandez M, Matsushita M, et al. Autosomal dominant sensory/motor neuropathy with Ataxia (SMNA): Linkage to chromosome 7q22-q32. Am J Med Genet 2002; 114:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/111\">",
"      Schelhaas HJ, Ippel PF, Hageman G, et al. Clinical and genetic analysis of a four-generation family with a distinct autosomal dominant cerebellar ataxia. J Neurol 2001; 248:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/112\">",
"      Verbeek DS, Schelhaas JH, Ippel EF, et al. Identification of a novel SCA locus ( SCA19) in a Dutch autosomal dominant cerebellar ataxia family on chromosome region 1p21-q21. Hum Genet 2002; 111:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/113\">",
"      Chung MY, Lu YC, Cheng NC, Soong BW. A novel autosomal dominant spinocerebellar ataxia (SCA22) linked to chromosome 1p21-q23. Brain 2003; 126:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/114\">",
"      Duarri A, Jezierska J, Fokkens M, et al. Mutations in potassium channel kcnd3 cause spinocerebellar ataxia type 19. Ann Neurol 2012; 72:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/115\">",
"      Lee YC, Durr A, Majczenko K, et al. Mutations in KCND3 cause spinocerebellar ataxia type 22. Ann Neurol 2012; 72:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/116\">",
"      Pulst SM, Otis TS. Repolarization matters: mutations in the Kv4.3 potassium channel cause SCA19/22. Ann Neurol 2012; 72:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/117\">",
"      Knight MA, Gardner RJ, Bahlo M, et al. Dominantly inherited ataxia and dysphonia with dentate calcification: spinocerebellar ataxia type 20. Brain 2004; 127:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/118\">",
"      Devos D, Schraen-Maschke S, Vuillaume I, et al. Clinical features and genetic analysis of a new form of spinocerebellar ataxia. Neurology 2001; 56:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/119\">",
"      Vuillaume I, Devos D, Schraen-Maschke S, et al. A new locus for spinocerebellar ataxia (SCA21) maps to chromosome 7p21.3-p15.1. Ann Neurol 2002; 52:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/120\">",
"      Verbeek DS, van de Warrenburg BP, Wesseling P, et al. Mapping of the SCA23 locus involved in autosomal dominant cerebellar ataxia to chromosome region 20p13-12.3. Brain 2004; 127:2551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/121\">",
"      Bakalkin G, Watanabe H, Jezierska J, et al. Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23. Am J Hum Genet 2010; 87:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/122\">",
"      Swartz BE, Burmeister M, Somers JT, et al. A form of inherited cerebellar ataxia with saccadic intrusions, increased saccadic speed, sensory neuropathy, and myoclonus. Ann N Y Acad Sci 2002; 956:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/123\">",
"      Swartz BE, Li S, Bespalova I, et al. Pathogenesis of clinical signs in recessive ataxia with saccadic intrusions. Ann Neurol 2003; 54:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/124\">",
"      Stevanin G, Bouslam N, Thobois S, et al. Spinocerebellar ataxia with sensory neuropathy (SCA25) maps to chromosome 2p. Ann Neurol 2004; 55:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/125\">",
"      Yu GY, Howell MJ, Roller MJ, et al. Spinocerebellar ataxia type 26 maps to chromosome 19p13.3 adjacent to SCA6. Ann Neurol 2005; 57:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/126\">",
"      van Swieten JC, Brusse E, de Graaf BM, et al. A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia [corrected]. Am J Hum Genet 2003; 72:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/127\">",
"      Brusse E, de Koning I, Maat-Kievit A, et al. Spinocerebellar ataxia associated with a mutation in the fibroblast growth factor 14 gene (SCA27): A new phenotype. Mov Disord 2006; 21:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/128\">",
"      Dalski A, Atici J, Kreuz FR, et al. Mutation analysis in the fibroblast growth factor 14 gene: frameshift mutation and polymorphisms in patients with inherited ataxias. Eur J Hum Genet 2005; 13:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/129\">",
"      Cagnoli C, Mariotti C, Taroni F, et al. SCA28, a novel form of autosomal dominant cerebellar ataxia on chromosome 18p11.22-q11.2. Brain 2006; 129:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/130\">",
"      Di Bella D, Lazzaro F, Brusco A, et al. Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat Genet 2010; 42:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/131\">",
"      Dudding TE, Friend K, Schofield PW, et al. Autosomal dominant congenital non-progressive ataxia overlaps with the SCA15 locus. Neurology 2004; 63:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/132\">",
"      Storey E, Bahlo M, Fahey M, et al. A new dominantly inherited pure cerebellar ataxia, SCA 30. J Neurol Neurosurg Psychiatry 2009; 80:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/133\">",
"      Ishikawa K, Toru S, Tsunemi T, et al. An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains. Am J Hum Genet 2005; 77:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/134\">",
"      Owada K, Ishikawa K, Toru S, et al. A clinical, genetic, and neuropathologic study in a family with 16q-linked ADCA type III. Neurology 2005; 65:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/135\">",
"      Onodera Y, Aoki M, Mizuno H, et al. Clinical features of chromosome 16q22.1 linked autosomal dominant cerebellar ataxia in Japanese. Neurology 2006; 67:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/136\">",
"      Sato N, Amino T, Kobayashi K, et al. Spinocerebellar ataxia type 31 is associated with \"inserted\" penta-nucleotide repeats containing (TGGAA)n. Am J Hum Genet 2009; 85:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/137\">",
"      Jiang H, Zhu HP, Gomez CM. SCA32: an autosomal dominant cerebellar ataxia with azoospermia maps to chromosome 7q32-q33 [abstract]. Mov Disord 2010; 25:S192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/138\">",
"      Giroux JM, Barbeau A. Erythrokeratodermia with ataxia. Arch Dermatol 1972; 106:183.",
"     </a>",
"    </li>",
"    <li>",
"     Turcotte Gauthier MT. &Eacute;tude clinique et g&eacute;n&eacute;tique d&rsquo;une nouvelle forme d&rsquo;ataxie spinoc&eacute;r&eacute;belleuse pure associ&eacute;e &agrave; l&rsquo;&Eacute;rythrok&eacute;ratodermie. MSc Thesis, Univ Montreal Faculte de Medecine, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/140\">",
"      Wang JL, Yang X, Xia K, et al. TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing. Brain 2010; 133:3510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/141\">",
"      Kobayashi H, Abe K, Matsuura T, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet 2011; 89:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/142\">",
"      Ikeda Y, Ohta Y, Kobayashi H, et al. Clinical features of SCA36: a novel spinocerebellar ataxia with motor neuron involvement (Asidan). Neurology 2012; 79:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/143\">",
"      Sugihara K, Maruyama H, Morino H, et al. The clinical characteristics of spinocerebellar ataxia 36: a study of 2121 Japanese ataxia patients. Mov Disord 2012; 27:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/144\">",
"      Garc&iacute;a-Murias M, Quint&aacute;ns B, Arias M, et al. 'Costa da Morte' ataxia is spinocerebellar ataxia 36: clinical and genetic characterization. Brain 2012; 135:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/145\">",
"      Onodera O, Oyake M, Takano H, et al. Molecular cloning of a full-length cDNA for dentatorubral-pallidoluysian atrophy and regional expressions of the expanded alleles in the CNS. Am J Hum Genet 1995; 57:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/146\">",
"      Egawa K, Takahashi Y, Kubota Y, et al. Electroclinical features of epilepsy in patients with juvenile type dentatorubral-pallidoluysian atrophy. Epilepsia 2008; 49:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/147\">",
"      Koide R, Onodera O, Ikeuchi T, et al. Atrophy of the cerebellum and brainstem in dentatorubral pallidoluysian atrophy. Influence of CAG repeat size on MRI findings. Neurology 1997; 49:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/148\">",
"      Silveira I, Lopes-Cendes I, Kish S, et al. Frequency of spinocerebellar ataxia type 1, dentatorubropallidoluysian atrophy, and Machado-Joseph disease mutations in a large group of spinocerebellar ataxia patients. Neurology 1996; 46:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/149\">",
"      Le Ber I, Camuzat A, Castelnovo G, et al. Prevalence of dentatorubral-pallidoluysian atrophy in a large series of white patients with cerebellar ataxia. Arch Neurol 2003; 60:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/150\">",
"      Brusco A, Gellera C, Cagnoli C, et al. Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families. Arch Neurol 2004; 61:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/151\">",
"      Wardle M, Majounie E, Williams NM, et al. Dentatorubral pallidoluysian atrophy in South Wales. J Neurol Neurosurg Psychiatry 2008; 79:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/152\">",
"      Nagafuchi S, Yanagisawa H, Ohsaki E, et al. Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidoluysian atrophy (DRPLA). Nat Genet 1994; 8:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/153\">",
"      Yazawa I, Nukina N, Hashida H, et al. Abnormal gene product identified in hereditary dentatorubral-pallidoluysian atrophy (DRPLA) brain. Nat Genet 1995; 10:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/154\">",
"      Igarashi S, Koide R, Shimohata T, et al. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet 1998; 18:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/155\">",
"      Ellerby LM, Andrusiak RL, Wellington CL, et al. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem 1999; 274:8730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/156\">",
"      Burke JR, Wingfield MS, Lewis KE, et al. The Haw River syndrome: dentatorubropallidoluysian atrophy (DRPLA) in an African-American family. Nat Genet 1994; 7:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/157\">",
"      Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001; 57:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/158\">",
"      Amiri K, Hagerman RJ, Hagerman PJ. Fragile X-associated tremor/ataxia syndrome: an aging face of the fragile X gene. Arch Neurol 2008; 65:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/159\">",
"      Apartis E, Blancher A, Meissner WG, et al. FXTAS: new insights and the need for revised diagnostic criteria. Neurology 2012; 79:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/160\">",
"      Oostra BA, Willemsen R. A fragile balance: FMR1 expression levels. Hum Mol Genet 2003; 12 Spec No 2:R249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/161\">",
"      Hagerman PJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome (FXTAS). Ment Retard Dev Disabil Res Rev 2004; 10:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/162\">",
"      Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet 2004; 74:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/163\">",
"      Brussino A, Gellera C, Saluto A, et al. FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia. Neurology 2005; 64:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/164\">",
"      Leehey MA, Berry-Kravis E, Goetz CG, et al. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology 2008; 70:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/165\">",
"      Hagerman RJ, Leavitt BR, Farzin F, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004; 74:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/166\">",
"      Rodriguez-Revenga L, Pagonabarraga J, G&oacute;mez-Anson B, et al. Motor and mental dysfunction in mother-daughter transmitted FXTAS. Neurology 2010; 75:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/167\">",
"      Berry-Kravis E, Potanos K, Weinberg D, et al. Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Ann Neurol 2005; 57:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/168\">",
"      Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003; 72:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/169\">",
"      Brunberg JA, Jacquemont S, Hagerman RJ, et al. Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. AJNR Am J Neuroradiol 2002; 23:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/170\">",
"      Cohen S, Masyn K, Adams J, et al. Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome. Neurology 2006; 67:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/171\">",
"      Greco CM, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006; 129:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/172\">",
"      Hall DA, Berry-Kravis E, Jacquemont S, et al. Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS). Neurology 2005; 65:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/173\">",
"      Toft M, Aasly J, Bisceglio G, et al. Parkinsonism, FXTAS, and FMR1 premutations. Mov Disord 2005; 20:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/174\">",
"      Garcia Arocena D, Louis ED, Tassone F, et al. Screen for expanded FMR1 alleles in patients with essential tremor. Mov Disord 2004; 19:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/175\">",
"      Kamm C, Healy DG, Quinn NP, et al. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 2005; 128:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/176\">",
"      Kamm C, Gasser T. The variable phenotype of FXTAS: a common cause of \"idiopathic\" disorders. Neurology 2005; 65:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/177\">",
"      Kretzschmar HA, Kufer P, Riethm&uuml;ller G, et al. Prion protein mutation at codon 102 in an Italian family with Gerstmann-Str&auml;ussler-Scheinker syndrome. Neurology 1992; 42:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/35/29242/abstract/178\">",
"      Guerrini L, Lolli F, Ginestroni A, et al. Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study. Brain 2004; 127:1785.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6230 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29242=[""].join("\n");
var outline_f28_35_29242=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H99235102\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF SCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H605308128\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLASSIFICATION OF SCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SCA1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SCA2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SCA3 (Machado-Joseph disease)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SCA4",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SCA5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SCA6",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SCA7",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SCA8",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SCA types 9 to 20",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SCA types 21 to 36",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DISORDERS THAT RESEMBLE SCA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Dentatorubral pallidoluysian atrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Haw River syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fragile X-associated tremor/ataxia syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Clinical features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - FMR1 DNA testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Gerstmann-Str&auml;ussler-Scheinker syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      EVALUATION OF THE PATIENT WITH AUTOSOMAL DOMINANT ATAXIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Electrophysiologic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H99235102\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6230\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6230|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/59/11198\" title=\"table 1\">",
"      Characteristics of SCA types",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7017?source=related_link\">",
"      Biology and genetics of prions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/30/26089?source=related_link\">",
"      Diagnosis of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31176?source=related_link\">",
"      Diseases of the central nervous system caused by prions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23450?source=related_link\">",
"      Epidemiology and pathogenesis of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/4/15432?source=related_link\">",
"      Friedreich ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7386?source=related_link\">",
"      Genetic and environmental causes of birth defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8599?source=related_link\">",
"      Huntington disease: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37433?source=related_link\">",
"      Overview of the hereditary ataxias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_35_29243="Isolation P marneffei";
var content_f28_35_29243=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sources of isolation of organism in HIV-infected patients with",
"    <em>",
"     Penicillium marneffei",
"    </em>",
"    infection",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Specimen",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Number of cases/total",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Thailand",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        India",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood",
"       </td>",
"       <td>",
"        59/78",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Skin",
"       </td>",
"       <td>",
"        47/52",
"       </td>",
"       <td>",
"        10/10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymph node",
"       </td>",
"       <td>",
"        9/9",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow",
"       </td>",
"       <td>",
"        26/26",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sputum",
"       </td>",
"       <td>",
"        14/41",
"       </td>",
"       <td>",
"        1/1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in southeast Asia. Lancet 1994; 344:110.",
"      <br>",
"       2. Ranjana KH, Priyokumar K, Singh TJ, et al. Disseminated Penicillium marneffei infection among HIV-infected patients in Manipur state, India. J Infect Dis 2002; 45:268.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29243=[""].join("\n");
var outline_f28_35_29243=null;
var title_f28_35_29244="Severity of pneumonia in infants and children";
var content_f28_35_29244=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Severity of community acquired pneumonia in infants and children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical features of mild pneumonia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features of severe pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Temperature &lt;38.5&deg;C (101.3&deg;F)",
"       </td>",
"       <td>",
"        Temperature &ge;38.5&deg;C (101.3&deg;F)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Mild or absent respiratory distress:",
"        </p>",
"        <ul>",
"         <li>",
"          Increased RR, but less than the age-specific RR that defines moderate to severe respiratory distress",
"         </li>",
"         <li>",
"          Mild or absent retractions",
"         </li>",
"         <li>",
"          No grunting",
"         </li>",
"         <li>",
"          No nasal flaring",
"         </li>",
"         <li>",
"          No apnea",
"         </li>",
"         <li>",
"          Mild shortness of breath",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         Moderate to severe respiratory distress:",
"        </p>",
"        <ul>",
"         <li>",
"          RR &gt;70 breaths/minute for infants; RR &gt;50 breaths/minute for older children",
"         </li>",
"         <li>",
"          Moderate/severe suprasternal, intercostal, or subcostal retractions (&lt;12 months)",
"         </li>",
"         <li>",
"          Severe difficulty breathing (&ge;12 months)",
"         </li>",
"         <li>",
"          Grunting",
"         </li>",
"         <li>",
"          Nasal flaring",
"         </li>",
"         <li>",
"          Apnea",
"         </li>",
"         <li>",
"          Significant shortness of breath",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal color",
"       </td>",
"       <td>",
"        Cyanosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal mental status",
"       </td>",
"       <td>",
"        Altered mental status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normoxemia (oxygen saturation &ge;92 percent in room air)",
"       </td>",
"       <td>",
"        Hypoxemia (sustained oxygen saturation &lt;90 percent in room air at sea level)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal feeding (infants); no vomiting",
"       </td>",
"       <td>",
"        Not feeding (infants) or signs of dehydration (older children)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal heart rate",
"       </td>",
"       <td>",
"        Tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Capillary refill &lt;2 seconds",
"       </td>",
"       <td>",
"        Capillary refill &ge;2 seconds",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RR: respiratory rate.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.",
"      </li>",
"      <li>",
"       Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66:ii1.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29244=[""].join("\n");
var outline_f28_35_29244=null;
var title_f28_35_29245="Methimazole versus PTU";
var content_f28_35_29245=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F54732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F54732&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Methimazole acts faster than PTU in Graves' hyperthyroidism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 261px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Time required for patients with Graves' hyperthyroidism to become euthyroid (normal serum T4 and T3 concentrations) after therapy with methimazole (10 mg three times daily, n = 66) or propylthiouracil (PTU, 100 mg three times daily, n = 17). The euthyroid state was achieved more quickly with methimazole (5.8 versus 16.8 weeks).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Okamura K, Ikenoue H, Shiroozu A, et al.&nbsp;Reevaluation of the effects of methylmercaptoimidazole and propylthiouracil in patients with Graves' hyperthyroidism. J Clin Endocrinol Metab 1987; 65:719.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29245=[""].join("\n");
var outline_f28_35_29245=null;
var title_f28_35_29246="Goals of therapy in ICU";
var content_f28_35_29246=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F81250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F81250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Goals of therapy in ICU",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 411px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29246=[""].join("\n");
var outline_f28_35_29246=null;
var title_f28_35_29247="Oblique view tibial plateau fracture";
var content_f28_35_29247=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Oblique view tibial plateau fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 338px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two oblique radiographs of the same knee demonstrate the usefulness of these views in cases of suspected fracture. The fracture of the lateral tibial plateau appears as a curvilinear area of radiolucency in one obllique view (left panel), while the same fracture is less easily appreciated on the other view (right panel, arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_35_29247=[""].join("\n");
var outline_f28_35_29247=null;
